



Article scientifique

Article

2021

Submitted version

Open Access

This is an author manuscript pre-peer-reviewing (submitted version) of the original publication. The layout of the published version may differ .

Lysosomal retargeting of Myoferlin mitigates membrane stress to enable pancreatic cancer growth

Gupta, Suprit; Yano, Julian; Mercier, Vincent; Htwe, Htet Htwe; Shin, Hijai R.; Rademaker, Gilles; Cakir, Zeynep; Ituarte, Thomas; Wen, Kwun W.; Kim, Grace E.; Zoncu, Roberto; Roux, Aurélien; Dawson, David W.; Perera, Rushika M.

How to cite

GUPTA, Suprit et al. Lysosomal retargeting of Myoferlin mitigates membrane stress to enable pancreatic cancer growth. In: Nature cell biology, 2021, vol. 23, n° 3, p. 232–242. doi: 10.1038/s41556-021-00644-7

This publication URL: <https://archive-ouverte.unige.ch//unige:157055>

Publication DOI: [10.1038/s41556-021-00644-7](https://doi.org/10.1038/s41556-021-00644-7)

1 **Lysosomal retargeting of Myoferlin mitigates membrane stress to enable**
2 **pancreatic cancer growth.**

3

4 Suprit Gupta¹, Julian Yano¹, Htet Htwe Htwe¹, Hijai R. Shin², Zeynep Cakir¹, Thomas
5 Ituarte¹, Kwun W. Wen³, Grace E. Kim³, Roberto Zoncu², David W. Dawson⁴, Rushika M.
6 Perera^{1,3,5*}

7

8 ¹*Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143, USA;* ²*Department of*
9 *Molecular and Cell Biology, University of California Berkeley, Berkeley, CA 94720;* ³*Department of Pathology,*
10 *University of California, San Francisco, San Francisco, CA 94143, USA;* ⁴*Department of Pathology and Laboratory*
11 *Medicine and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los*
12 *Angeles, Los Angeles, CA 90095-1732, USA;* ⁵*Helen Diller Family Comprehensive Cancer Center, University of*
13 *California, San Francisco, San Francisco, CA 94158, USA.*

14

15

16

17 * Corresponding author: R.M.P (rushika.perera@ucsf.edu)

18 **Abstract**

19 Lysosomes must maintain integrity of their limiting membrane to ensure efficient fusion
20 with incoming organelles and degradation of substrates within their lumen. Pancreatic
21 cancer cells upregulate lysosomal biogenesis to enhance nutrient recycling and stress
22 resistance, but whether dedicated programs for maintaining lysosomal membrane
23 integrity facilitate pancreatic cancer growth is unknown. Using proteomic-based organelle
24 profiling, we identify the Ferlin family plasma membrane repair factor, Myoferlin, as
25 selectively and highly enriched on the membrane of pancreatic cancer lysosomes.
26 Mechanistically, lysosome localization of Myoferlin is necessary and sufficient for
27 maintenance of lysosome health and provides an early-acting protective system against
28 membrane damage that is independent from the endosomal sorting complex required for
29 transport (ESCRT)-mediated repair network. Myoferlin is upregulated in human
30 pancreatic cancer, predicts poor survival, and its ablation severely impairs lysosome
31 function and tumour growth *in vivo*. Thus, retargeting of plasma membrane repair factors
32 enhances pro-oncogenic activities of the lysosome.

33 Lysosomes function as critical nodes for macromolecular recycling, vesicle
34 trafficking, metabolic reprogramming, and pro-growth signaling in the cell¹⁻³. Pancreatic
35 ductal adenocarcinoma (PDA), are highly reliant on enhanced lysosome function to
36 facilitate degradation, clearance and recycling of cellular material delivered by increased
37 rates of vesicle trafficking through autophagy and macropinocytosis⁴⁻⁹. To cope with the
38 increased flux of substrates delivered to the lysosome for degradation, PDA cells
39 upregulate transcriptional programs for lysosome biogenesis, which are mediated by the
40 MiT/TFE factors^{6,10}. Although enhanced MiT/TFE activity leads to a dramatic increase in
41 the number of lysosomes⁶, whether qualitative differences endow PDA lysosomes with
42 unique structural and functional properties to cope with higher rates of vesicle trafficking
43 and substrate clearance remains unknown.

44 An emerging aspect is the susceptibility of lysosomes to undergo membrane
45 damage due to various cellular stressors. In response to damage, several mechanisms
46 ensure proper lysosomal integrity and function by responding to damage and facilitating
47 repair or removal of dysfunctional lysosomes^{11,12}. These pathways include repair via the
48 Endosomal Sorting Complex Required for Transport (ESCRT), a multi-subunit
49 membrane-remodeling machinery that performs membrane bending and scission away
50 from the cytoplasm¹². ESCRT components were recently shown to polymerize on the
51 limiting membrane of lysosomes challenged with membrane-damaging agents, where
52 they facilitate repair of 'microtears' likely through scission and resealing of the free
53 membrane edges^{13,14}. When ESCRT recruitment to damage sites is blocked, more
54 permanent and severe damage to lysosome function results. A second pathway facilitates
55 clearance of irreversibly damaged or dysfunctional lysosomes via a selective
56 macroautophagy process, termed lysophagy^{11,15-17}.

57 PDA cells are unusual in their ability to import and degrade a large variety and
58 quantity of intracellular and extracellular substrates to the lysosomal lumen in order to
59 sustain unrestrained growth in nutrient-poor microenvironments. While it is likely that this
60 enhanced substrate intake may pose unique challenges, it remains unknown whether
61 cancer-specific mechanisms for lysosomal membrane stabilization enable PDA cells to
62 cope with higher susceptibility to organelle stress. To answer this question, we conducted
63 mass spectrometry-based profiling of immuno-isolated lysosomes captured from PDA

64 and non-PDA cells. We uncovered profound differences in the protein content and
65 composition of PDA lysosomes and identified members of the Ferlin family of membrane
66 repair factors, Myoferlin (MYOF) and Dysferlin (DYSF) as membrane proteins uniquely
67 enriched in PDA lysosome fractions, with MYOF being broadly upregulated in PDA cell
68 lines and patient samples. We find that lysosomal MYOF protects against a variety of
69 membrane stressors to sustain enhanced functionality of PDA lysosomes. Accordingly,
70 MYOF depletion in PDA cells triggers constitutive lysosomal membrane damage, leading
71 to profound defects in lysosome morphology and function and arrested PDA tumour
72 growth. Importantly, MYOF is upregulated in patient PDA specimens and high levels are
73 predictive of poor patient prognosis, thus implicating MYOF as a key regulator of
74 lysosome function and PDA tumour growth.

75 **Results**

76 **Organelle proteomics identifies the Ferlin repair factors as PDA specific lysosomal**
77 **membrane proteins.**

78 To identify novel proteins specific to PDA lysosomes, we captured intact
79 lysosomes via affinity purification from cells stably expressing the lysosome membrane
80 protein TMEM192 fused to mRFP and 3x HA tag (T192-mRFP-3xHA; LysoTag) (**Fig. 1a;**
81 **Supplementary Fig. 1a**). Expression of LysoTag allows for efficient and rapid capture of
82 intact lysosomes from cells that are amenable to mass spectrometry-based proteomics
83 analysis^{18,19}. Comparative analysis of proteins present in lysosome fractions from PDA
84 cells (PaTu8988T) versus non-PDA cells (HEK293T) identified 376 proteins with ≥ 2 -fold
85 enrichment in PDA lysosomal elutes (**Supplementary Table 1**). Analysis of the biological
86 processes and pathways associated with these enriched PDA lysosomal proteins
87 identified pathways associated with metabolism (“fatty acid degradation”, “valine, leucine,
88 isoleucine degradation”, “central carbon metabolism in cancer”), as well as cell adhesion
89 (“focal adhesion”, “ECM-receptor interaction”) (**Fig. 1b**). Moreover, we noted that proteins
90 associated with “vesicle-mediated trafficking” (eg. RAB22A, SNX11) and “endocytosis”
91 (eg. CLTB, DNML1, PACSIN3, ITSN1, EZR) were significantly enriched in PDA lysosome
92 elutes consistent with heightened rates of vesicle trafficking converging on the lysosome
93 in PDA cells (**Fig. 1b,c; Supplementary Table 2**). Moreover, several autophagy related
94 proteins were enriched in PDA lysosomes, such as LC3B, GABARAP2 and autophagy
95 receptors (NBR1, WDFY3, SEC62, TEX264, P62), consistent with increased rates of
96 autophagy in PDA (**Fig. 1d,e**). As a control, levels of LAMP1 were similar in HEK293T
97 and PaTu8988T lysosomes (**Fig. 1d,e**).

98 Interestingly, two of the most significantly enriched proteins in PDA lysosome
99 fractions were Myoferlin (MYOF; 30-fold enriched) and Dysferlin (DYSF; 89.6-fold
100 enriched) (**Fig. 1d,e**), both of which belong to the Ferlin family of membrane repair
101 factors²⁰⁻²². We first validated the PDA-specific enrichment of MYOF and DYSF via direct
102 immunoblotting of lysosomal fractions from HPDE (human pancreatic ductal epithelial
103 cells) and a panel of PDA cells expressing LysoTag. Consistent with our proteomics data,
104 PaTu8988T lysosome fractions expressed both MYOF and DYSF (**Fig. 1f**). Lysosomes
105 isolated from KP4 and MiaPaca cells also displayed high levels of MYOF relative to HPDE

106 lysosomes (**Fig. 1f**). Moreover, lysosomal enrichment of Ferlins correlated with their
107 elevated expression in multiple PDA lines, whereas these proteins showed low or
108 undetectable expression in a panel of non-PDA cells (**Fig. 1g**). Of note, MYOF transcript
109 and protein levels were broadly upregulated in virtually all human PDA cell lines while
110 DYSF upregulation was restricted to 3 cell lines (**Supplementary figure 1b**) with
111 PaTu8988T cells having higher levels of DYSF relative to MYOF (**Fig. 1g**).

112 Prior studies have shown that Ferlin proteins localize predominantly to the plasma
113 membrane, where they facilitate repair of the lipid bilayer in tissues subjected to
114 heightened mechanical stress, particularly in skeletal muscle cells^{21,23,24}. Accordingly,
115 mutations in DYSF are associated with two forms of muscular dystrophy; Limb Girdle
116 Muscular Dystrophy type 2B (LGMD2B) and Miyoshi Myopathy (MM), whereby impaired
117 membrane resealing compromises myoblast maturation, fusion and plasma membrane
118 repair^{20,25,26}. Our lysosomal mass spectrometry analysis suggests that, in PDA cells,
119 Ferlin proteins may be retargeted to the lysosomal membrane. Consistent with this
120 hypothesis, transient expression of MYOF-HA in PDA cells (KP4, PaTu8902, MiaPaca
121 and Panc0203) followed by immuno-fluorescence staining confirmed a punctate
122 distribution of MYOF which colocalized with LAMP2 positive lysosomes, with little or no
123 detectable signal on the plasma membrane (**Fig. 1h; Supplementary Fig. 1c**). In
124 contrast, MYOF-HA localized to the plasma membrane or showed a diffuse cytoplasmic
125 localization in non-PDA cells with no visible overlap with LAMP2-positive structures (**Fig.**
126 **1h; Supplementary Fig. 1d**). To further confirm the differential subcellular targeting of
127 MYOF in PDA versus non-PDA cells we performed biotin labeling of surface proteins in
128 KP4 cells and HEK293T cells transiently expressing MYOF-HA followed by streptavidin-
129 mediated immunoprecipitation. Consistent with the immunofluorescence results, we find
130 that endogenous MYOF is not biotinylated in KP4 cells and therefore absent from the
131 plasma membrane (**Fig. 1i**). In contrast MYOF transiently expressed in HEK293T cells
132 was efficiently biotinylated, consistent with its plasma membrane localization in these
133 cells (**Fig. 1h,i**). Thus, Myoferlin is both upregulated and show substantial retargeting to
134 the lysosome in PDA cells. Given the preferential upregulation of MYOF in PDA cells
135 relative to HPDE, we focused our functional analysis on this Ferlin family member in
136 subsequent experiments.

137 To establish that MYOF resides on the outer (cytoplasm-facing) leaflet of the
138 lysosomal membrane rather than being trafficked to the lysosomal lumen for degradation,
139 we first treated cells with the lysosome V-ATPase inhibitor Bafilomycin A1 (BafA1) to
140 inhibit lysosomal degradation. BafA1 treatment led to a progressive accumulation of
141 known cargo proteins such as the autophagy receptor p62 (**Supplementary Fig. 1e**). In
142 contrast MYOF did not show an increase in levels upon BafA1 treatment suggesting that
143 it is unlikely to be a cargo protein brought to the lysosome for degradation.

144 To further prove that MYOF is anchored to the cytoplasmic face of the lysosomal
145 membrane, we treated affinity-captured PDA lysosomes with increasing concentrations
146 of proteinase K, with the expectation that cytoplasmic facing proteins would be sensitive
147 to proteinase K digestion while luminal proteins would be protected. As expected, luminal
148 proteins (LC3, Cathepsin C) and luminal facing proteins (LAMP2) were protected from
149 proteinase K digestion, whereas membrane proteins exposed to the cytoplasm such as
150 NPC1 were progressively digested with increasing concentrations of proteinase K (**Fig.**
151 **1j**). MYOF showed rapid digestion by proteinase K, confirming that it is a membrane
152 protein present on the outer surface of the lysosome (**Fig. 1j**). Taken together these data
153 indicate that MYOF is topologically anchored via its C-terminal transmembrane domain
154 to the outer lysosomal membrane, with its N-terminus extending into the cytoplasm.

155

156 **PDA lysosomes display enhanced protection against membrane damage.**

157 Given a known function for Ferlin proteins in maintenance and repair of membrane,
158 we sought to determine whether lysosomal localization of MYOF might confer enhanced
159 protection against membrane damage. To do so, we compared the response of PDA
160 lysosomes versus non-PDA lysosomes under conditions that mimic various forms of
161 lysosomal stress. We first employed acute, chemically-induced lysosomal membrane
162 damage by treating cells with LLOMe (L-Leucyl-L-leucine O-methyl ester), a well-
163 established lysosomotropic agent commonly used to rupture endolysosomal
164 membranes^{13,14,27}. LLOMe rapidly and efficiently accumulates within the lumen of acidic
165 organelles where it is converted by the lysosomal protease Cathepsin C into a polymer
166 capable of causing small ruptures in the membrane²⁷. To test the response of lysosomes
167 to the LLOMe challenge, cells were preloaded with LysoTracker red dye, which

168 accumulates within intact lysosomes, and the rate of dye leakage induced by LLOMe was
169 measured over time. While lysosomes in non-PDA cells (HPDE, U20S and HEK293T)
170 lost virtually all lysotracker red staining within 15min of LLOMe treatment (**Fig. 2a;**
171 **Supplementary Fig. 2a**), consistent with progressive lysosomal membrane rupture, PDA
172 lysosomes retained the Lysotracker dye for longer time periods (**Fig. 2a,b**). This effect
173 was not due to reduced Cathepsin C-dependent activation of LLOMe in PDA lysosomes,
174 as Cathepsin C levels were similar, if not higher in PDA cells relative to HPDE cells
175 (**Supplementary Fig. 2b**). Prior studies have also established that particulate material
176 such as crystals of silica, alum and uric acid are capable of damaging vesicles and
177 lysosomal membrane¹⁴. Similarly, changes in osmolarity have also been shown to cause
178 changes in endolysosome membrane tension and permeability²⁸. Therefore, we
179 measured the response of PDA and non-PDA cells to these additional forms of
180 endolysosome membrane damage. Consistent with our observations with LLOMe, we
181 find that PDA lysosomes are more resistant to silica-induced and hypertonic sucrose-
182 induced membrane damage as measured by reduced loss of Lysotracker red dye signal
183 (**Supplementary Fig. 2c-f**). Collectively, these data suggest that, relative to non-PDA
184 counterparts, PDA lysosomes are capable of withstanding diverse membrane perturbing
185 agents, relative to non-PDA lysosomes.

186 Along with its degradative functions, the lysosome serves as the platform for
187 nutrient signaling via the mechanistic target of rapamycin complex 1 (mTORC1), which
188 must localize to the lysosome surface^{1,19} and requires an intact lysosomal membrane in
189 order to be activated¹⁶. Treatment of HPDE cells with LLOMe over a 1h time course led
190 to a rapid decrease in mTORC1 signaling as measured by phosphorylation of
191 downstream targets p70S6K and 4EBP1 (**Fig. 2c**). In contrast, PDA cells retained
192 mTORC1 signaling activity throughout the 1h LLOMe treatment duration (**Fig. 2c;**
193 **Supplementary Fig. 2g**). Similarly, a 4-fold lower dose of LLOMe was sufficient to
194 suppress mTORC1 signaling in HPDE cells, while PDA cells retained mTORC1 signaling
195 even at the highest dose of LLOMe tested (**Supplementary Fig. 2h**).

196 Recent studies showed that lysosomal membrane disruption is accompanied by
197 rapid recruitment of ESCRT machinery that facilitates membrane repair^{13,14}. ESCRT
198 proteins are organized into sub-complexes; ESCRT III proteins (CHMPs 1-7 and IST1)

199 are responsible for mediating membrane constriction and fission whereas ALIX (ESCRT
200 II) and TSG101 (ESCRT I) facilitate recruitment of ESCRT III components to the site of
201 damage^{13,14}. Immunofluorescence staining following a time course of LLOMe, Silica or
202 hypertonic sucrose treatment showed that HPDE cells rapidly recruit ALIX to lysosomes
203 post treatment (**Supplementary Fig. 3a-c**). In contrast, identically treated KP4 cells
204 showed a significant delay in ALIX recruitment (**Supplementary Fig. 3a-c**). Similarly,
205 LLOMe treatment lead to rapid requirement of ESCRT III proteins CHMP3 and CHMP1A
206 as early as 1min post treatment in HPDE cells and was significantly delayed in PDA cells
207 (**Fig. 2d,e; Supplementary Fig. 3d,e**). Additional markers of lysosomal membrane
208 damage include the Galectins – cytoplasmic proteins that recognize and bind to
209 inappropriately exposed glycans on the luminal side of lysosomal membrane
210 proteins^{15,17,29,30}. Within 15min of LLOMe treatment 45% of LAMP2 positive lysosomes in
211 HPDE cells recruited Galectin 3 (GAL3) (**Fig. 2f,g**). In contrast, only 8% of lysosomes in
212 PDA cells recruited GAL3, which showed predominantly diffuse staining in PDA cells even
213 after 30min of LLOMe treatment (**Fig. 2f,g**). To further confirm differential recruitment of
214 GAL3 to lysosomes in response to LLOMe in KP4 and HPDE cells we captured intact
215 lysosomes from LysoTag expressing cells following treatment with LLOMe for 10 minutes.
216 Lysosomes purified from LLOMe treated HPDE cells contained higher levels of GAL3 as
217 measured by immunoblot, compared to lysosomes purified from identically treated KP4
218 cells (**Supplementary Fig. 3f**). These findings support the notion that PDA lysosomes
219 display enhanced protection against acute membrane damage compared to their non-
220 PDA counterparts.

221

222 **Myoferlin is required to maintain lysosome function in PDA cells.**

223 The unique protein composition of PDA lysosomes may help maintain their
224 membrane integrity and function in response to stress. Based on the known membrane
225 repair functions of the Ferlins, we next tested whether lysosomal localization of MYOF
226 could explain the increased stress resistance observed of PDA lysosomes. Suppression
227 of MYOF expression via shRNA mediated knockdown or CRISPR mediated knockout in
228 PDA cell lines led to lysosomes with aberrant morphology and increased diameter (**Fig.**
229 **3a; Supplementary Fig. 4a-d**) – a phenotype commonly associated with lysosome

230 dysfunction^{31,32}. Electron microscopy analysis of PDA cells following knockdown of MYOF
231 confirmed an abundance of enlarged lysosomes which lacked intraluminal content (**Fig.**
232 **3b**). This phenotype is distinct from general inhibition of lysosome digestion following
233 treatment with lysosomotropic agents (Chloroquine), V-ATPase inhibitors (BafA1)³³ or
234 knockdown of MiT/TFE transcription factors⁶, which commonly result in distended
235 lysosomes filled with undigested, electron-dense content. Consistent with this idea,
236 MYOF deficient lysosomes were unable to accumulate intraluminal LysoTracker dye
237 (**Supplementary Fig. 4e**). Importantly, MYOF loss triggered a spontaneous lysosomal
238 membrane stress response, associated with constitutive localization of ESCRT proteins
239 ALIX, CHMP3 and CHMP1A to LAMP1 positive lysosomes (**Fig. 3c,d; Supplementary**
240 **Fig. 4f**). Together, the alteration in lysosome morphology, lack of LysoTracker dye
241 retention and constitutive recruitment of ESCRT proteins suggests that MYOF serves to
242 protect against lysosome dysfunction in PDA cells. Accordingly, knockdown of MYOF
243 caused a marked accumulation of lipidated LC3B by immunoblotting (**Fig. 3e**) and
244 increased LC3B-positive puncta by immunofluorescence (**Fig. 3f; Supplementary Fig.**
245 **4g**) as well as delayed clearance of macropinocytosed serum albumin, indicating
246 defective lysosomal proteolysis (**Supplementary Fig. 4h**). Moreover, loss of MYOF also
247 led to reduced baseline mTORC1 signaling as measured by phosphorylation of p70S6K
248 and 4EBP1, which was suppressed further following treatment with LLOMe
249 (**Supplementary Fig. 4i**). These data support a novel role for MYOF in maintenance of
250 lysosome function in PDA cells.

251 PDA cells are characterized by elevated autophagy and macropinocytosis, which
252 delivers intracellular and extracellular cargo, respectively, to the lysosome for
253 degradation^{4,7,8}. This increased cargo trafficking may create a unique dependency on
254 MYOF to maintain membrane stability and efficient lysosome function. Therefore,
255 reducing the incoming flux of membrane trafficking should decrease the dependency of
256 PDA cells on MYOF. To explore this idea, we tested whether blocking autophagosome
257 formation and trafficking via knockdown of ATG3 or ATG7 might prevent the lysosomal
258 membrane stress observed in MYOF KO cells. Knockdown of ATG3 or ATG7 in MYOF
259 KO cells led to reduced autophagy as evidenced by accumulation of p62 and unlipidated
260 LC3B-I (**Fig. 3g**). Strikingly, autophagy suppression resolved the lysosome stress

261 response induced by MYOF loss, as indicated by reduced ALIX recruitment to lysosomes
262 in MYOF KO cells (**Fig. 3h,i**). These data suggest that the increased vesicle trafficking
263 characteristic of PDA cells imparts heightened stress on the lysosome in order to fuse,
264 process and clear incoming cargo; this stress is counteracted by increased expression
265 and lysosomal targeting of MYOF.

266

267 **Inducible lysosome targeting of MYOF is sufficient to protect against acute** 268 **membrane damage.**

269 To gain insights into the mechanism of MYOF-mediated lysosomal stabilization,
270 we tested whether inducible targeting of MYOF to the lysosomal membrane in non-PDA
271 cells would be sufficient to protect against LLOMe-mediated damage. To do so, we used
272 a heterodimerization system (FKBP-FRB) to inducibly recruit a variant of MYOF lacking
273 its C-terminal transmembrane domain (MYOF Δ TM) (**Fig. 4a**), to the lysosome membrane
274 following addition of a rapamycin-derived chemical dimerizer AP21967 (AP)^{34,35} (**Fig. 4b**).
275 U2OS cells were first engineered to stably express the FKBP module conjugated to the
276 C-terminus of the lysosomal membrane protein TMEM192 (T192-Flag-FKBP)^{34,35}, which
277 we confirmed localizes to LAMP2 positive lysosomes (**Fig. 4c**). These cells were then
278 transiently transfected with MYOF Δ TM conjugated to FRB* (referred to hereafter as
279 MYOF-FRB*). In the absence of AP, MYOF-FRB* showed a diffuse cytoplasmic
280 localization (**Fig. 4d; top**) in T192-Flag-FKBP expressing U2OS cells. Upon treatment
281 with AP, MYOF-FRB* was massively recruited to LAMP2 positive lysosomes (**Fig. 4d;**
282 **bottom**). Without AP treatment, addition of LLOMe to U2OS cells led to recruitment of
283 ALIX (**Fig. 4e**) and GAL3 (**Supplementary Fig. 5a**) to lysosomes as expected. However,
284 following addition of AP and the resulting recruitment of MYOF-FRB* to lysosomes,
285 recruitment of ALIX and GAL3 to lysosomes was significantly reduced in response to
286 LLOMe (**Fig. 4e; Supplementary Fig. 5a**). These data suggest that targeting of MYOF
287 to the membrane of non-PDA lysosomes is sufficient to confer protection against
288 chemically induced membrane damage.

289 The first three C2 domains of MYOF have been shown to bind membrane lipids,
290 alter their distribution^{36,37} and recruit accessory proteins³⁸ and are therefore thought to be
291 key mediators of the membrane resealing functions of MYOF and DYSF. We therefore

292 tested whether a variant of MYOF lacking C2A, C2B and C2C domains (MYOF Δ C2)
293 would lead to loss of membrane protection following LLOMe-mediated damage in non-
294 PDA cells. Unlike MYOF-FRB*, AP mediated recruitment of the MYOF Δ C2-FRB* mutant
295 to T192-Flag-FKBP positive lysosomes was unable to prevent LLOMe-induced damage,
296 as shown by unchanged ALIX and GAL3 recruitment irrespective of the AP dimerizer
297 (**Fig. 4f; Supplementary Fig. 5b**). These data establish the N-terminal C2 domains of
298 MYOF as mediating its protective function at the lysosome.

299

300 **Loss of MYOF leads to impaired *in vivo* tumour growth.**

301 Given the established role for lysosomes as mediators of cellular adaptation and
302 growth in PDA, we next determined the impact of MYOF loss on PDA growth *in vitro* and
303 *in vivo*. Similar to human PDA cell lines (**Fig. 1g**), tumours isolated from a genetically
304 engineered mouse model of PDA (p48-Cre;LSL-Kras^{G12D};Trp53^{L/+}; referred to here as
305 KPC)³⁹ displayed levels of Myof that were higher than normal pancreas and liver, and
306 comparable to mouse C2C12 muscle cells (**Fig. 5a**). Dysf also showed higher levels in
307 KPC tumours relative to normal pancreas (**Fig. 5a**). Importantly, Myof expression in KPC
308 tumours was restricted to CK19 positive tumour epithelia and did not show significant
309 overlap with α -SMA positive stromal cells (**Fig. 5b**). CRISPR mediated knockout of Myof
310 in murine KPC cells⁴⁰ led to accumulation of LC3B-II, reduced accumulation of
311 LysoTracker dye and reduced *in vivo* growth following transplantation in syngeneic hosts
312 (**Supplementary Fig. 6a-d**). Similarly, shRNA mediated knockdown or CRISPR mediated
313 knockout of MYOF in KP4 cells significantly reduced colony forming ability (**Fig. 5c**) and
314 *in vivo* tumour growth (**Fig. 5d,e**). Resected tumours also showed a decrease in
315 proliferation as measured by Ki67 staining (**Fig. 5f**). Together these data strongly support
316 a critical role for MYOF as a novel lysosomal membrane protein essential for maintenance
317 of organelle function during tumour growth *in vivo*.

318

319 **MYOF levels dictate worse prognosis in PDA patients.**

320 Consistent with high expression levels of MYOF in human PDA cell lines and
321 murine KPC tumours, analysis of several publicly available patient PDA datasets showed
322 that MYOF transcript levels were significantly higher in human PDA tumours relative to

323 normal pancreas or adjacent non-neoplastic tissue (**Fig. 6a**). In addition, semi-
324 quantitative immunohistochemical analysis revealed significantly increased MYOF
325 protein expression in patient-matched neoplastic versus non-neoplastic epithelium (n =
326 102, $P < 2.2 \times 10^{-25}$) with average histoscores of 3.95 ± 2.3 versus 0.57 ± 0.82 ,
327 respectively. Further dichotomization (histoscores >5 versus ≤ 5) revealed high MYOF in
328 23% of PDA versus 0% of adjacent normal pancreas, (n = 102; $P < 0.0001$) (**Fig. 6b,c**).
329 No significant associations were noted between high MYOF PDA and clinicopathologic
330 parameters except for a significant correlation with female gender ($P = 0.008$;
331 **Supplementary Table 3**). Notably, high MYOF PDA was associated with worse overall
332 survival in univariate analysis (hazard ratio = 2.03; 95% CI = 1.29-3.19; **Supplementary**
333 **Table 4a**) with a median overall survival of 19.4 months compared to 32 months for
334 patients with low MYOF PDA (log rank $P = 0.002$, **Fig. 6d**). High MYOF expression was
335 also an independent predictor of worse overall survival in multivariate Cox regression
336 analysis (**Supplementary Table 4b**). Moreover, a significant correlation between high
337 MYOF expression and worse overall survival was confirmed in an independent PDA
338 patient cohort from The Cancer Genome Atlas (**Fig. 6e**). Together, analyses from these
339 clinical datasets support a role for MYOF and enhanced lysosome function as predictors
340 of shortened survival in PDA patients.

341 **Discussion**

342

343 Our findings demonstrate that PDA lysosomes are intrinsically more capable of
344 withstanding membrane stress than non-cancer lysosomes. Retargeting of the Ferlin
345 family of plasma membrane repair factors to the lysosomal membrane is critical for this
346 ability and helps to maintain the structural integrity and pro-tumourigenic activities of this
347 organelle. Lysosomal targeting of the Ferlins appears to be an adaptive mechanism in
348 response to the increased degradative burden placed on PDA lysosomes by elevated
349 influx of autophagic and macropinocytic vesicle trafficking (**Fig. 6f**). Consistent with this
350 model, inhibition of autophagy relieves the lysosomal membrane stress that accumulated
351 following MYOF loss.

352 The nature of the membrane stress that PDA lysosomes undergo may derive from
353 the specific cargo being degraded, such as large protein aggregates of intracellular or
354 extracellular origin, oxidative damage as well as alterations in membrane composition
355 due to continuous fusion with autophagy-derived and plasma membrane-derived
356 vesicles. Ferlins may counteract this stress through several mechanisms, including
357 formation of oligomers that structurally stabilize the lipid bilayer, thus preventing its
358 rupture, as well as promoting fusion with other vesicles that act as membrane donors to
359 reseal damage that has already occurred. Both mechanisms have been proposed to
360 underlie Ferlin-mediated repair of the plasma membrane of skeletal muscle cells and may
361 operate at the lysosomal membrane in PDA cells as well^{21,23,24,37}.

362 Our findings also suggest that MYOF either replaces or delays activation of a major
363 membrane repair system mediated by the ESCRT complex. ESCRT is thought to repair
364 membrane ‘microtears’ through scission of the free membrane edge into the lumen and
365 resealing of the ‘neck’ driven by subunit polymerization^{21,23,24,37}. In turn, this resealing
366 activity is critical to prevent exposure and leakage of luminal lysosomal proteins and
367 protein domains. In the simplest model, the membrane-stabilizing action of MYOF may
368 inhibit or delay ESCRT recruitment by preventing the formation of exposed microtears.
369 Consistent with this idea, loss of MYOF in PDA cells triggers spontaneous ESCRT
370 recruitment to the lysosome. More direct mechanisms of Ferlin mediated ESCRT
371 regulation may also occur, such as competition for a common binding partner.

372 Alternatively, Ferlin proteins may represent a new protective mechanism in cells highly
373 reliant on the lysosome for growth. Given that ESCRT proteins have diverse functions at
374 multiple cellular locations¹², a dedicated lysosomal program may confer more efficient
375 monitoring and maintenance of lysosomal health.

376 Accordingly, loss of MYOF leads to severe lysosomal dysfunction and significantly
377 impairs PDA tumour growth *in vivo*, establishing a critical role for this protein in promoting
378 the pro-oncogenic functions of the lysosome in cancer. PDA cells rely on lysosomes as
379 an important source of metabolites² and the lysosome regulates levels of essential
380 micronutrients including iron^{41,42} and calcium⁴³ that can be exchanged with other
381 organelles in the cell including the ER^{44,45} and mitochondria^{41,42}. Thus, lysosome
382 dysfunction following MYOF loss could indirectly impact additional organelles and cellular
383 metabolic processes. In line with this hypothesis, prior studies^{46,47} showed that MYOF
384 loss in cancer cells caused respiratory defects in mitochondria, an organelle where MYOF
385 is not found. Finally, high MYOF expression distinguishes a cohort of patient PDA
386 tumours that predict worse overall survival. Several other cancers also show elevated
387 MYOF expression⁴⁷⁻⁵⁰ however a role for MYOF in regulation of lysosome function in
388 these cancers remains unknown.

389 Our findings highlight unique features of cancer lysosomes and identify a
390 dedicated protective mechanism essential for maintenance of lysosomal health. Blocking
391 this protective function of MYOF may pave the way for new lysosome-centered strategies
392 for inhibiting PDA and other cancers.

393 **Acknowledgements**

394 We thank all the members of the Perera lab and Debnath Lab for helpful discussions. R.M.P is
395 the Nadia's Gift Foundation Innovator of the Damon Runyon Cancer Research Foundation (DRR-
396 46-17) and is additionally supported by an NIH Director's New Innovator Award (1DP2CA216364),
397 the Pancreatic Cancer Action Network Career Development Award, and the Hirshberg Foundation
398 for Pancreatic Cancer. H.R.S. is supported by an AACR-Amgen fellowship in
399 Clinical/Translational Cancer Research. R.Z is supported by grants from the NIH (R01GM127763,
400 R01GM130995), a Damon Runyon-Rachleff Innovator Award, Edward Mallinckrodt, Jr.
401 Foundation Grant. D.W.D. receives support from the Hirshberg Foundation for Pancreatic Cancer
402 Research. We thank Reena Zalpuri at the University of California Berkeley Electron Microscope
403 Laboratory for advice and assistance in electron microscopy sample preparation and data
404 collection.

405

406 **Author contributions**

407 S.G. performed the majority of experiments and drafted the manuscript. J.Y. developed the FKBP-
408 FRB assay, conducted surface biotinylation experiments, molecular cloning and data analysis.
409 H.H.H. assisted with mouse experiments and immuno-histochemistry. H.R.S. performed the
410 electron microscopy. Z.C. performed the proteinase K protection assay T.I conducted data and
411 pathway analysis. K.W.W and G.K provided pathology analysis of patient samples. R.Z. provided
412 intellectual feedback, reagents and supervised H.R.S. D.W.D provided the PDA TMA and
413 conducted independent pathology analysis and statistical testing. R.M.P. conceived the project,
414 supervised the research, wrote and edited the manuscript.

415

416 **Competing interests**

417 The other authors declare no competing interests.

418


419 **References**

- 420 1 Lawrence, R. E. & Zoncu, R. The lysosome as a cellular centre for signalling, metabolism
421 and quality control. *Nat Cell Biol* **21**, 133-142, doi:10.1038/s41556-018-0244-7 (2019).
- 422 2 Perera, R. M. & Zoncu, R. The Lysosome as a Regulatory Hub. *Annu Rev Cell Dev Biol*
423 **32**, 223-253, doi:10.1146/annurev-cellbio-111315-125125 (2016).
- 424 3 Ballabio, A. & Bonifacino, J. S. Lysosomes as dynamic regulators of cell and organismal
425 homeostasis. *Nat Rev Mol Cell Biol* **21**, 101-118, doi:10.1038/s41580-019-0185-4 (2020).
- 426 4 Commisso, C. *et al.* Macropinocytosis of protein is an amino acid supply route in Ras-
427 transformed cells. *Nature* **497**, 633-637, doi:10.1038/nature12138 (2013).
- 428 5 Kamphorst, J. J. *et al.* Human pancreatic cancer tumors are nutrient poor and tumor cells
429 actively scavenge extracellular protein. *Cancer Res* **75**, 544-553, doi:10.1158/0008-
430 5472.CAN-14-2211 (2015).
- 431 6 Perera, R. M. *et al.* Transcriptional control of autophagy-lysosome function drives
432 pancreatic cancer metabolism. *Nature* **524**, 361-365, doi:10.1038/nature14587 (2015).
- 433 7 Yang, A. *et al.* Autophagy is critical for pancreatic tumor growth and progression in tumors
434 with p53 alterations. *Cancer Discov* **4**, 905-913, doi:10.1158/2159-8290.CD-14-0362
435 (2014).
- 436 8 Yang, S. *et al.* Pancreatic cancers require autophagy for tumor growth. *Genes Dev* **25**, 717-
437 729, doi:10.1101/gad.2016111 (2011).
- 438 9 Yamamoto, K. *et al.* Autophagy promotes immune evasion of pancreatic cancer by
439 degrading MHC-I. *Nature* **581**, 100-105, doi:10.1038/s41586-020-2229-5 (2020).
- 440 10 Perera, R. M., Di Malta, C. & Ballabio, A. MiT/TFE Family of Transcription Factors,
441 Lysosomes, and Cancer. *Annu Rev Cancer Biol* **3**, 203-222, doi:10.1146/annurev-
442 cancerbio-030518-055835 (2019).
- 443 11 Papadopoulos, C., Kravic, B. & Meyer, H. Repair or Lysophagy: Dealing with Damaged
444 Lysosomes. *J Mol Biol* **432**, 231-239, doi:10.1016/j.jmb.2019.08.010 (2020).
- 445 12 Vietri, M., Radulovic, M. & Stenmark, H. The many functions of ESCRTs. *Nat Rev Mol*
446 *Cell Biol* **21**, 25-42, doi:10.1038/s41580-019-0177-4 (2020).
- 447 13 Radulovic, M. *et al.* ESCRT-mediated lysosome repair precedes lysophagy and promotes
448 cell survival. *EMBO J* **37**, doi:10.15252/embj.201899753 (2018).
- 449 14 Skowyra, M. L., Schlesinger, P. H., Naismith, T. V. & Hanson, P. I. Triggered recruitment
450 of ESCRT machinery promotes endolysosomal repair. *Science* **360**,
451 doi:10.1126/science.aar5078 (2018).
- 452 15 Hung, Y. H., Chen, L. M., Yang, J. Y. & Yang, W. Y. Spatiotemporally controlled
453 induction of autophagy-mediated lysosome turnover. *Nat Commun* **4**, 2111,
454 doi:10.1038/ncomms3111 (2013).
- 455 16 Jia, J. *et al.* Galectins Control mTOR in Response to Endomembrane Damage. *Mol Cell*
456 **70**, 120-135 e128, doi:10.1016/j.molcel.2018.03.009 (2018).
- 457 17 Maejima, I. *et al.* Autophagy sequesters damaged lysosomes to control lysosomal
458 biogenesis and kidney injury. *EMBO J* **32**, 2336-2347, doi:10.1038/emboj.2013.171
459 (2013).
- 460 18 Abu-Remaileh, M. *et al.* Lysosomal metabolomics reveals V-ATPase- and mTOR-
461 dependent regulation of amino acid efflux from lysosomes. *Science* **358**, 807-813,
462 doi:10.1126/science.aan6298 (2017).

- 463 19 Zoncu, R. *et al.* mTORC1 senses lysosomal amino acids through an inside-out mechanism
464 that requires the vacuolar H(+)-ATPase. *Science* **334**, 678-683,
465 doi:10.1126/science.1207056 (2011).
- 466 20 Bansal, D. & Campbell, K. P. Dysferlin and the plasma membrane repair in muscular
467 dystrophy. *Trends Cell Biol* **14**, 206-213, doi:10.1016/j.tcb.2004.03.001 (2004).
- 468 21 Bansal, D. *et al.* Defective membrane repair in dysferlin-deficient muscular dystrophy.
469 *Nature* **423**, 168-172, doi:10.1038/nature01573 (2003).
- 470 22 Davis, D. B., Delmonte, A. J., Ly, C. T. & McNally, E. M. Myoferlin, a candidate gene
471 and potential modifier of muscular dystrophy. *Hum Mol Genet* **9**, 217-226,
472 doi:10.1093/hmg/9.2.217 (2000).
- 473 23 Doherty, K. R. *et al.* Normal myoblast fusion requires myoferlin. *Development* **132**, 5565-
474 5575, doi:10.1242/dev.02155 (2005).
- 475 24 Lek, A., Evesson, F. J., Sutton, R. B., North, K. N. & Cooper, S. T. Ferlins: regulators of
476 vesicle fusion for auditory neurotransmission, receptor trafficking and membrane repair.
477 *Traffic* **13**, 185-194, doi:10.1111/j.1600-0854.2011.01267.x (2012).
- 478 25 Bashir, R. *et al.* A gene related to *Caenorhabditis elegans* spermatogenesis factor *fer-1* is
479 mutated in limb-girdle muscular dystrophy type 2B. *Nat Genet* **20**, 37-42,
480 doi:10.1038/1689 (1998).
- 481 26 Liu, J. *et al.* Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and
482 limb girdle muscular dystrophy. *Nat Genet* **20**, 31-36, doi:10.1038/1682 (1998).
- 483 27 Repnik, U. *et al.* L-leucyl-L-leucine methyl ester does not release cysteine cathepsins to
484 the cytosol but inactivates them in transiently permeabilized lysosomes. *J Cell Sci* **130**,
485 3124-3140, doi:10.1242/jcs.204529 (2017).
- 486 28 Mercier, V. *et al.* Endosomal membrane tension regulates ESCRT-III-dependent intra-
487 luminal vesicle formation. *Nat Cell Biol* **22**, 947-959, doi:10.1038/s41556-020-0546-4
488 (2020).
- 489 29 Chauhan, S. *et al.* TRIMs and Galectins Globally Cooperate and TRIM16 and Galectin-3
490 Co-direct Autophagy in Endomembrane Damage Homeostasis. *Dev Cell* **39**, 13-27,
491 doi:10.1016/j.devcel.2016.08.003 (2016).
- 492 30 Thurston, T. L., Wandel, M. P., von Muhlinen, N., Foeglein, A. & Randow, F. Galectin 8
493 targets damaged vesicles for autophagy to defend cells against bacterial invasion. *Nature*
494 **482**, 414-418, doi:10.1038/nature10744 (2012).
- 495 31 Kilpatrick, B. S., Eden, E. R., Hockey, L. N., Futter, C. E. & Patel, S. Methods for
496 monitoring lysosomal morphology. *Methods Cell Biol* **126**, 1-19,
497 doi:10.1016/bs.mcb.2014.10.018 (2015).
- 498 32 Platt, F. M., Boland, B. & van der Spoel, A. C. The cell biology of disease: lysosomal
499 storage disorders: the cellular impact of lysosomal dysfunction. *J Cell Biol* **199**, 723-734,
500 doi:10.1083/jcb.201208152 (2012).
- 501 33 Mauthe, M. *et al.* Chloroquine inhibits autophagic flux by decreasing autophagosome-
502 lysosome fusion. *Autophagy* **14**, 1435-1455, doi:10.1080/15548627.2018.1474314 (2018).
- 503 34 Lawrence, R. E. *et al.* A nutrient-induced affinity switch controls mTORC1 activation by
504 its Rag GTPase-Ragulator lysosomal scaffold. *Nat Cell Biol* **20**, 1052-1063,
505 doi:10.1038/s41556-018-0148-6 (2018).
- 506 35 Liberles, S. D., Diver, S. T., Austin, D. J. & Schreiber, S. L. Inducible gene expression and
507 protein translocation using nontoxic ligands identified by a mammalian three-hybrid
508 screen. *Proc Natl Acad Sci U S A* **94**, 7825-7830, doi:10.1073/pnas.94.15.7825 (1997).

- 509 36 Davis, D. B., Doherty, K. R., Delmonte, A. J. & McNally, E. M. Calcium-sensitive
510 phospholipid binding properties of normal and mutant ferlin C2 domains. *J Biol Chem* **277**,
511 22883-22888, doi:10.1074/jbc.M201858200 (2002).
- 512 37 Marty, N. J., Holman, C. L., Abdullah, N. & Johnson, C. P. The C2 domains of otoferlin,
513 dysferlin, and myoferlin alter the packing of lipid bilayers. *Biochemistry* **52**, 5585-5592,
514 doi:10.1021/bi400432f (2013).
- 515 38 Doherty, K. R. *et al.* The endocytic recycling protein EHD2 interacts with myoferlin to
516 regulate myoblast fusion. *J Biol Chem* **283**, 20252-20260, doi:10.1074/jbc.M802306200
517 (2008).
- 518 39 Lee, J. J. *et al.* Stromal response to Hedgehog signaling restrains pancreatic cancer
519 progression. *Proc Natl Acad Sci U S A* **111**, E3091-3100, doi:10.1073/pnas.1411679111
520 (2014).
- 521 40 Hingorani, S. R. *et al.* Preinvasive and invasive ductal pancreatic cancer and its early
522 detection in the mouse. *Cancer Cell* **4**, 437-450, doi:10.1016/s1535-6108(03)00309-x
523 (2003).
- 524 41 Weber, R. A. *et al.* Maintaining Iron Homeostasis Is the Key Role of Lysosomal Acidity
525 for Cell Proliferation. *Mol Cell* **77**, 645-655 e647, doi:10.1016/j.molcel.2020.01.003
526 (2020).
- 527 42 Yambire, K. F. *et al.* Impaired lysosomal acidification triggers iron deficiency and
528 inflammation in vivo. *Elife* **8**, doi:10.7554/eLife.51031 (2019).
- 529 43 Xu, H. & Ren, D. Lysosomal physiology. *Annu Rev Physiol* **77**, 57-80,
530 doi:10.1146/annurev-physiol-021014-071649 (2015).
- 531 44 Dong, R. *et al.* Endosome-ER Contacts Control Actin Nucleation and Retromer Function
532 through VAP-Dependent Regulation of PI4P. *Cell* **166**, 408-423,
533 doi:10.1016/j.cell.2016.06.037 (2016).
- 534 45 Lim, C. Y. *et al.* ER-lysosome contacts enable cholesterol sensing by mTORC1 and drive
535 aberrant growth signalling in Niemann-Pick type C. *Nat Cell Biol* **21**, 1206-1218,
536 doi:10.1038/s41556-019-0391-5 (2019).
- 537 46 Rademaker, G. *et al.* Myoferlin controls mitochondrial structure and activity in pancreatic
538 ductal adenocarcinoma, and affects tumor aggressiveness. *Oncogene* **37**, 4398-4412,
539 doi:10.1038/s41388-018-0287-z (2018).
- 540 47 Rademaker, G. *et al.* Human colon cancer cells highly express myoferlin to maintain a fit
541 mitochondrial network and escape p53-driven apoptosis. *Oncogenesis* **8**, 21,
542 doi:10.1038/s41389-019-0130-6 (2019).
- 543 48 Cox, A. *et al.* Knockdown of Myoferlin Suppresses Migration and Invasion in Clear-Cell
544 Renal-Cell Carcinoma. *Anticancer Res* **40**, 3119-3128, doi:10.21873/anticancer.14293
545 (2020).
- 546 49 Turtoi, A. *et al.* Myoferlin is a key regulator of EGFR activity in breast cancer. *Cancer Res*
547 **73**, 5438-5448, doi:10.1158/0008-5472.CAN-13-1142 (2013).
- 548 50 Blomme, A. *et al.* Myoferlin regulates cellular lipid metabolism and promotes metastases
549 in triple-negative breast cancer. *Oncogene* **36**, 2116-2130, doi:10.1038/onc.2016.369
550 (2017).
- 551
- 552

Fig. 1 | Organelle proteomics identifies the Ferlin repair factors as PDA specific lysosome associated membrane proteins.



553


554

555 **Fig. 1 | Organelle proteomics identifies the Ferlin repair factors as PDA specific lysosome**
 556 **associated membrane proteins.**

557 **a.** Schematic showing lysosome purification using affinity-based capture from cells stably
 558 expressing *T192-mRFP-3xHA*. **b.** KEGG pathway analysis of ≥ 2 -fold enriched PDA lysosome
 559 associated proteins. **c.** Volcano plot of lysosome proteomics data from non-PDA (HEK293T) and

560 PDA (PaTu8988T) cells. Data are plotted as log₂ fold change (PDA/non-PDA) versus the -log₁₀
561 of the p-value. ≥2-fold enriched proteins associated with “vesicle mediated trafficking” are
562 indicated in dark red and overlapping proteins associated with “endocytosis” are indicated in
563 pink/blue. **d.** Identical volcano plot as in (c) indicating autophagy related proteins (orange) and
564 MYOF and DYSF (red). **e.** Average peptide counts for the indicated proteins from n = 3 biological
565 replicates. **f.** Immunoprecipitation of purified lysosomes from the indicated cell lines showing
566 enrichment of MYOF and DYSF in PDA lysosome fractions. LAMP2 serves as a loading control
567 while absence of AIF, PDI and RCAS1 confirm organelle purity. **g.** Immunoblot showing levels of
568 MYOF and restricted expression of DYSF in the indicated human cell lines (PDA highlighted in
569 blue). **h.** Immuno-fluorescence staining of MYOF-HA (green) and LAMP2 (red) in HEK293T (left)
570 and KP4 (right) cells. Arrowheads indicate plasma membrane localization of MYOF in HEK293T
571 cells and lysosome localization in KP4 cells. Scale, 20μm, inset scale, 2μm. **i.** Biotinylation of cell
572 surface proteins in KP4 and HEK293T cells expressing MYOF-HA. Biotinylated proteins were
573 immuno-precipitated and western-blotted for MYOF. Note, MYOF is not on the cell surface of KP4
574 cells while MYOF-HA is present on the cell surface when expressed in HEK293T cells. **j.** Affinity
575 purified lysosomes were treated with increasing concentrations of Proteinase K as indicated.
576 Intraluminal proteins are protected from degradation (LAMP2, Cathepsin C, LC3B) while extra-
577 luminal proteins are sensitive to digestion (NPC1 and MYOF).
578

Fig. 2 | PDA lysosomes are more resistant to lysosome membrane damage.



579

580

Fig. 2 | PDA lysosomes are more resistant to lysosome membrane damage.

581

582

583

584

585

586

587

588

589

590

591


592

593

a. Time-course of lysotracker red staining in HPDE, KP4 and PaTu8902 following treatment with LLOMe. (HPDE n = 76, 80, 81, 80; KP4 n = 80, 77, 80, 82; PaTu8902 n = 96, 96, 81, 82 cells). **b.** Quantification of normalized fold change in lysotracker red stain in HPDE, U20S, 293T, KP4 and PaTu8902 cells treated with LLOMe. Data are mean \pm s.e.m from n = 60-96 cells per timepoint for each cell line. *P* values determined by two-way ANOVA. **c.** Immunoblots for the indicated proteins in HPDE and KP4 cells following time course treatment with LLOMe. **d.** HPDE and KP4 cells with and without LLOMe treatment were co-stained for CHMP3 (green) and LAMP1 (red). **e.** Quantification of percentage co-localization in control and LLOMe treated cells. (HPDE n = 50, 51, 50, 51; KP4 n = 51, 50, 50, 50 cells). **f.** HPDE and KP4 cells expressing GFP-Galectin 3 (green) were treated with LLOMe for the indicated times and co-stained for LAMP2 (red). **g.** Quantification of percentage co-localization in control and LLOMe treated cells. (HPDE n = 39,

594 43, 40, 42; KP4 n = 43, 42, 40, 42 cells). Scale, 20 μ m. Data are mean \pm s.d. *P* values determined
595 by unpaired two-tailed *t*-tests. **** *P* < 0.0001.

Fig. 3 | MYOF is essential for lysosome function in PDA cells.




596

597 **Fig. 3 | MYOF is essential for lysosome function in PDA cells.**

598 **a.** Immunofluorescence staining of LAMP2 (red) following CRISPR mediated knockout of MYOF
599 and Cas9 control KP4 cells. Graph at right shows measurement of lysosome diameter from n =
600 252 (Cas9 control), 251 (KO#1, KO#2). **b.** Representative electron microscopy images showing
601 aberrant lysosome morphology in KP4 cells following shRNA mediated knockdown of MYOF.
602 Arrowheads highlight differential lysosome morphology in shGFP versus shMYOF conditions.
603 Graph on the right shows quantification of lysosome diameter (n = 200 lysosomes from control; n
604 = 202 lysosomes from MYOF KD cells). Scale bar 1 μ m. **c, d.** Increased recruitment of ALIX
605 (green) (f) and CHMP3 (green) (g) to LAMP1 positive lysosomes (red) following KO of MYOF in
606 KP4 cells relative to Cas9 control cells. Graphs show the quantification of percentage ALIX (n =
607 60) and CHMP3 (n = 57) co-localization with LAMP1. **e.** Immunoblot showing increased LC3B
608 lipidation (arrowheads) in KP4 and 8902 cells upon siRNA or shRNA mediated knockdown of
609 MYOF. **f.** Immunofluorescence staining for LC3B (green) showing increase accumulation of LC3B
610 positive autophagosomes in KP4 cells following shRNA mediated knockdown of MYOF compared
611 to control cells. **i.** Graph on the right shows quantification of LC3B puncta (n = 14 fields/condition).
612 **g.** Immunoblot confirming shRNA mediated knockdown of ATG3 and ATG7 and autophagy
613 blockade in KP4 MYOF KO cells. **h.** Recruitment of ALIX (green) to lysosomes (LAMP1; red) in
614 KP4 cells in the presence (WT; n = 14) and absence (KO; n = 14) of MYOF. shRNA mediated
615 knockdown of ATG3 (n = 14, 15) or ATG7 (n = 15, 16) to suppress autophagy causes a decrease
616 in lysosome localization of ALIX in MYOF KO cells. **i.** Graph on the right shows quantification of
617 ALIX puncta per condition. Scale, 20 μ m. Data are mean \pm s.d. *P* values determined by unpaired
618 two-tailed *t*-tests. ** *P* < 0.01; *** *P* < 0.001.


Fig. 4 | The N Terminal C2 domains of MYOF are required for membrane protection.



619
620

621 **Fig. 4 | The N terminal C2 domains of MYOF are required for membrane protection.**
622 **a.** Domain structure of MYOF and MYOF-FRB* variants. **b.** Schematic showing
623 heterodimerization of MYOF-FRB* to lysosome membrane anchored T192-Flag-FKBP following
624 addition of the rapalogue (AP21967; AP). TM, transmembrane domain. **c.** Lysosomal localization
625 of T192-Flag-FKBP (Flag) in stably expressing U20S cells. **d.** Transient expression of MYOF-
626 FRB* (MYOF; detected with anti-HA antibody) in U20S cells stably expressing T192-Flag-FKBP.
627 In the absence of AP, MYOF-FRB* is cytoplasmic while upon AP addition MYOF Δ TM is recruited
628 to LAMP2 positive lysosomes (red). **e.** Recruitment of MYOF-FRB* protects against LLOMe
629 induced damage and ALIX recruitment. U20S-T192-Flag-FKBP expressing cells transfected with
630 MYOF-FRB* were treated with LLOMe for the indicated time points in the absence (n = 30, 24,
631 24 cells) or presence (n = 30, 27, 27 cells) of AP, followed by immuno-staining for HA (green) and
632 ALIX (red). **f.** U20S-T192-Flag-FKBP cells transfected with MYOF Δ C2-FRB were treated as in 'e'
633 (- AP n = 29 cells; + AP n = 29 cells) followed by immuno-staining for HA (green) and ALIX (red).
634 Lysosomal recruitment of MYOF Δ C2 does not protect against LLOMe induced ALIX recruitment.
635 Graphs at right show quantification of ALIX spots per cell in response to LLOMe. Scale for all
636 panels, 20 μ m. Data are mean \pm s.d. *P* values determined by unpaired two-tailed *t*-tests. * *P* <
637 0.05; ** *P* < 0.01; n.s. not significant.

Fig. 5 | MYOF is required for PDA tumor growth




638

639

Fig. 5 | MYOF is required for PDA tumor growth.

641 **a.** Expression levels of Myof and Dysf in mouse KPC derived PDA tumours relative to normal
 642 liver, normal pancreas and the mouse myoblast cell line, C2C12. **b.** Immuno-fluorescence staining
 643 of Myof (green), the epithelial marker CK19 (red; top) and the stromal marker α -SMA (red, bottom)
 644 in mouse KPC tumours showing co-localization of Myof with CK19 (open arrowheads) but not α -
 645 SMA (close arrow heads). Scale, 50 μ m. **c.** Colony formation of shGFP or shMYOF infected KP4
 646 cells. Graph shows quantification of colony area per condition from n = 9 independent
 647 experiments. **d.** *In vivo* growth in nude mice of s.c. KP4 xenografts following CRISPR mediated
 648 KO of MYOF. N = 9 (CTRL), 10 (KO#1), 10 (KO#2) tumours per group. Error bars represent s.e.m.
 649 **e.** Images (left) and tumour weight (right) of control and MYOF KO KP4 xenografts resected at
 650 day 42. n.t. no macroscopic tumour identified upon resection. **f.** Ki67 staining of control and MYOF
 651 KO xenografts. Graph shows quantification of Ki67 positive nuclei from n = 56 (control), 46
 652 (KO#1), 46 (KO#2) fields from 3-4 tumours per group. Scale, 100 μ m.

Fig. 6 | High MYOF expression levels correlate with aggressive disease




653
654
655

Fig. 6 | High MYOF expression levels correlate with aggressive disease

656 **a.** *MYOF* transcript levels in human PDA specimens and normal pancreas (adjacent non-
657 neoplastic tissue) from the indicated datasets. **b.** Immuno-histochemistry showing increased
658 expression of MYOF in primary patient PDA tumour epithelia (arrowheads) compared to normal
659 pancreas or adjacent stroma (asterisk). Scale, 100 μ m. **c.** Percentage distribution of semi-
660 quantitative histoscore of MYOF staining across normal adjacent (n = 102) and primary PDA (n =
661 136). **d, e.** High expression of MYOF predicts shorter overall survival in two patient cohorts. N =
662 136 patients in the UCLA cohort (MYOF high n=31, MYOF low n=105) and n = 185 in The Cancer
663 Genome Atlas (TCGA) cohort (MYOF high; Z score > 1, n = 27; MYOF low Z score < 1, n = 158).
664 p-Value calculated by Log-rank test. **f.** Model comparing lysosomal response to stress in normal
665 (left) and PDA (right) cells. Lysosomal retargeting of MYOF in PDA cells provides protection
666 against membrane stress caused by increased rates of vesicular traffic. Loss of MYOF renders
667 PDA lysosomes more vulnerable to damage. Data are mean \pm s.d. *P* values determined by
668 unpaired two-tailed *t*-tests.

Supplementary. Fig. 1 | MYOF is a novel lysosomal membrane protein in PDA cells.



669


670

Supplementary Figure 1 | MYOF is a novel lysosomal membrane protein in PDA cells.

672 **a.** Co-localization of T192-mRFP-3xHA and endogenous LAMP2 in KP4 cells. **b.** qRT-PCR
673 analysis of *MYOF* and *DYSF* mRNA levels across 10 human PDA cell lines. **c,d.** Immuno-
674 fluorescence staining of MYOF-HA (green) and LAMP2 (red) in PDA cell lines (MiaPaca,
675 Patu8902 and Panc0203) (c) and non-PDA (U2OS and HPDE) cell lines (d). Arrowheads show

676 examples of co-localization. **e.** Treatment of KP4, MiaPaCa and PaTu8988T cells with 75nM
677 BafA1 for the indicated times causes an increase in p62 levels but not MYOF or DYSF. Graph
678 shows the quantification of normalized fold change relative to LAMP1, averaged from 3
679 independent experiments. Scale, 20 μ m for all panels.

Supplementary. Fig. 2 | PDA lysosomes are resistant to multiple membrane perturbing agents.




680

681 **Supplementary Figure 2 | PDA lysosomes are resistant to multiple membrane perturbing**
682 **agents.**

683 **a.** Time-course of lysotracker red staining in 293T and U20S cells following treatment with
684 LLOMe. (293T, n = 80 cells per time point; U20S, n = 57 – 63 cells per time point). **b.** Immunoblot
685 showing the expression of Cathepsin C and Cathepsin B in the indicated cell lines. Asterisk
686 denotes cell lines used throughout the study. **c.** Time-course of lysotracker red staining in HPDE
687 and KP4 cells following treatment with 0.5M sucrose. (HPDE, n = 64 cells per time point; KP4, n
688 = 63 cells per time point). **d.** Normalized fold change of lysotracker staining. **e.** Time-course of
689 lysotracker red staining in HPDE and KP4 cells following treatment with 100 µg/ml silica. (HPDE,
690 n = 65 cells per time point; KP4, n = 65 cells per time point). **f.** Normalized fold change of
691 lysotracker staining. **g.** Immunoblots for the indicated proteins in MiaPaca cells following a time
692 course of 1mM LLOMe treatment. **h.** Immunoblots for the indicated proteins in HPDE, KP4 and
693 MiaPaca cells following treatment for 1hr with increasing doses of LLOMe. Scale, 20µm for all
694 panels. Data are mean ± s.d. *P* values determined by unpaired two-tailed *t*-tests. **** *P* < 0.0001.


Supplementary. Fig. 3 | Recruitment of ESCRT proteins to PDA lysosomes is delayed following acute damage



696 **Supplementary Figure 3 | Recruitment of ESCRT proteins to PDA lysosomes is delayed**
697 **following acute damage.**

698 **a-c.** Time course of LLOMe (a), 0.5M sucrose (b), 100 µg/ml silica (c) treatment of HPDE and
699 KP4 cells followed by immuno-fluorescence staining for ALIX (green) and LAMP1 (red). Graphs
700 show the quantification of percentage co-localization of ALIX (LLOMe, n = 60; sucrose, n = 13-15
701 fields/conditions; silica, n = 12-14 fields/condition per cell line) with LAMP1 positive lysosomes.
702 **d.** Time course of LLOMe treatment of HPDE and KP4 cells followed by immuno-fluorescence
703 staining for CHMP1A (green) and LAMP1 (red). **e.** Graph shows quantification of percentage co-
704 localization of CHMP1A (n = 40 per cell line) with LAMP1 positive lysosomes. **f.** Immunoblot for
705 the indicated proteins in lysosome fractions and flow through fractions isolated from HPDE- and
706 KP4-T192-mRFP-3xHA stable cell lines treated with LLOMe for 10min. Scale, 20µm. Data are
707 mean ± s.d. *P* values determined by unpaired two-tailed *t*-tests. ** *P* < 0.01; *** *P* < 0.001; **** *P*
708 < 0.0001.

Supplementary. Fig. 4 | MYOF loss leads to lysosome dysfunction in PDA cells.




709

710 **Supplementary Figure 4 | MYOF loss leads to lysosome dysfunction in PDA cells.**

711 **a.** Immunoblot showing the efficiency of MYOF ablation in KP4 and PaTu8902 CRISPR KO
712 clones. **b.** MYOF KO in PaTu8902 cells causes aberrant lysosomal morphology and increased
713 size as shown by LAMP2 staining (arrowheads). Graph on the right shows the measurement of
714 lysosome diameter in Cas9 control cells (n = 252), MYOF KO #1 (n = 255) and MYOF KO #2 (n
715 = 258). **c, d.** shRNA mediated knockdown of MYOF in PaTu8902 (c) and KP4 (d) cells leads to
716 defects in lysosome morphology and size as shown by LAMP2 staining (arrowheads). Graphs on
717 the right show the measurement of lysosome diameter [8902 shGFP (n = 258), shMYOF#1 (n =
718 256), shMYOF#2 (n = 263); KP4 shGFP (n = 254), shMYOF#1 (n = 239), shMYOF#2 (n = 243)
719 cells]. **e.** LysoTracker staining in KP4 cells following infection with shRNA against GFP or MYOF.
720 Graph on the right shows the quantification of normalized fold change in LysoTracker fluorescence
721 in control (shGFP, n = 70 cells) and KD (shMYOF#1, n = 65; shMYOF#2, n = 77) conditions. **f.**
722 Increased recruitment of CHMP1A (green) to LAMP1 positive lysosomes (red) following KO of
723 MYOF (#1, n = 60; #2, n = 61) in KP4 cells relative to Cas9 control (n = 58) cells. Graph shows
724 the quantification of percentage CHMP1A co-localization with LAMP1. **g.** Immuno-fluorescence
725 staining for LC3B in PaTu8902 cells following infection with shGFP (n = 55 cells) or shRNA
726 mediated knockdown of MYOF (#1, n = 57; #2, n = 58 cells). Graph on the right shows the
727 quantification of LC3B puncta. **h.** Proteolysis of macropinocytosed protein is impaired following
728 shRNA mediated knockdown of MYOF or BafA1 treatment as determined by pulse-chase with
729 DQ-BSA. Degradation of DQ-BSA in lysosomes is quantified (number of fluorescent spots/cell co-
730 localizing with LAMP2 positive lysosomes from n = 54 (shGFP), 57 (shMYOF#1), 52 (shMYOF#2),
731 54 (BafA1 treated) cells. **i.** Immunoblots for the indicated proteins in KP4 control cells (shGFP) or
732 following shRNA mediated knockdown of MYOF, with or without 1mM LLOMe treatment to
733 determine mTORC1 signaling activity. Data are mean \pm s.d. Scale, 20 μ m for all panels. *P* values
734 determined by unpaired two-tailed *t*-tests. * *P* < 0.05; ** *P* < 0.01; *** *P* < 0.001; **** *P* < 0.0001.


Supplementary. Fig. 5 | Lysosomal targeting of MYOF delays onset of membrane damage.



735

736 **Supplementary Figure 5 | Lysosomal targeting of MYOF delays onset of membrane**
 737 **damage.**

738 **a.** U20S cells stably expressing T192-Flag-FKBP and transiently transfected with MYOF-FRB*
 739 were treated with 1mM LLOMe for the indicated time points in the presence or absence of AP,
 740 followed by immuno-staining for HA (green) and Galectin 3 (GAL3; red). Recruitment of MYOF-
 741 FRB* (green) protects against LLOMe induced Gal3 recruitment [n= 40 (control), 39 (15mins), 43
 742 (30 mins), 41 (120mins) cells in the absence of AP and n = 39 (control), 45 (15mins), 41 (30mins)
 743 and 39 (120mins) cells in the presence of AP]. **b.** U20S cells stably expressing T192-Flag-FKBP
 744 and transfected with MYOF Δ C2-FRB* variant were treated as in 'a', followed by immuno-staining
 745 for HA (green) and ALIX (red). Recruitment of MYOF Δ C2 (green) does not protect against LLOMe
 746 induced ALIX recruitment [n = 26 cells per condition (-AP and +AP)]. Graphs at right show
 747 quantification of GAL3 (top) and ALIX (bottom) spots per cell in response to LLOMe. Scale, 20 μ m
 748 for all panels. Data are mean \pm s.d. P values determined by unpaired two-tailed t-tests. ** P <
 749 0.01; *** P < 0.001; n.s. not significant.



750
751

752 **Supplementary Figure 6 | MYOF is required for PDA tumour growth.**

753 **a.** Immunoblot of the indicated proteins in mouse KPC cells (FC1245) following CRISPR mediated
754 knockout of Myof. **b.** Graph showing increased accumulation of LC3B positive autophagosomes
755 in FC1245 Myof KO cells quantified from $n = 11$ fields per condition. Data are mean \pm s.d. **c.**
756 Graph showing decrease in lysotracker red staining in FC1245 Myof KO cells compared to Cas9
757 control cells, quantified from $n = 70$ (Cas9 control), 71 (KO#1), 70 (KO#2) cells per condition.
758 Data are mean \pm s.d. **d.** Growth rate of Cas9 control and Myof KO FC1245 allografts following
759 s.c. transplantation in syngeneic C57BL/6 host mice ($n = 5-6$ animals per group). Data represent
760 mean \pm s.e.m. P values determined by unpaired two-tailed t -tests. * $P < 0.05$; ** $P < 0.01$; *** P
761 < 0.001 .

762 **Methods**

763 **Cell culture and reagents.**

764 The cell lines HPDE, PaTu-8988T, KP4, MiaPaca2, Panc 2.03, PaTu-8902, Panc1,
765 AsPc1, HPAFII, YAPC, Panc 3.27, Panc 10.05, Capan 2 and HupT3 were obtained from the
766 American Type Culture Collection (ATCC) or the DSMZ. Cells were cultured in the following
767 media: PaTu-8988T, KP4, MiaPaca2, PaTu-8902, Panc1, AsPc1, HPAFII, YAPC, Capan2,
768 HEK293T in DMEM supplemented with 10% FBS; Panc 2.03, Panc 3.27, Panc 10.05 and HupT3
769 in RPMI with 10% FBS; HPDE cells were cultured in keratinocyte serum-free (KSF) medium
770 supplemented by epidermal growth factor and bovine pituitary extract (Life Technologies, Inc.,
771 Grand Island, NY). Cell lines were regularly tested and verified to be mycoplasma negative using
772 MycoAlert Detection Kit (Lonza).

773 FC1245 cells were established from *Pdx1-Cre*⁺, *Kras*^{LSL-G12D/+}, *Trp53*^{R172H/+} mice that were
774 backcrossed into a C57BL/6 background and were a gift from David Tuveson (CSHL). Murine
775 PDA cells were maintained in DMEM (Corning) supplemented with 10% FBS (Atlanta Biologicals
776 S11550H) and 1% Pen/Strep (Gibco). Cells were grown in a humidified incubator with 5% CO₂
777 at 37°C. Cultures were routinely verified to be negative for mycoplasma by PCR. Cell lines were
778 authenticated by fingerprinting, and low passage cultures were carefully maintained in a central
779 lab cell bank.

780 L-leucyl-L-leucine methyl ester (L7393) and Bafilomycin A1 (B1793) were purchased from
781 Sigma and used at 1mM concentration and 100nM respectively. Concentrated stock solutions
782 were prepared in dimethyl sulfoxide (DMSO) and stored at -80 °C in single-use aliquots. Silica
783 nanoparticles (cat.no. tlr-sio; InvivoGen, San Diego, CA, USA) were suspended in ultrapure water
784 according to manufactures instructions and diluted in complete growth medium to 100 µg/ml. For
785 hypertonic shock, 0.5M sucrose was made in complete growth medium and cells were incubated
786 for the indicated time points. Lyotracker Red-DND-99 (L7528) was purchased from Thermo
787 scientific and used at 75nM. DQ-BSA purchased from Thermo scientific (D12050).

788

789 **Constructs.**

790 pcDNA3.1-Myoferlin-HA and peGFP-hGalectin-3 was purchased from Addgene (plasmid no.
791 22443 and 73080 respectively). T192-RFP-3xHA - was generated by subcloning the cDNA of
792 TMEM192 (Origene) together with monomeric Red Fluorescent Protein (mRFP) and 3xHA tag
793 into the Nhe1 and EcoR1 sites of pLJM1 lentiviral vector (addgene plasmid no. 134631) as
794 previously described⁹. To generate MYOF Δ TM-HA-FRB*, first an AgeI cut-site was knocked into
795 the pcDNA3.1-Myoferlin-HA plasmid immediately prior to the transmembrane domain by site-

796 directed mutagenesis (Agilent: 210518). Second, a gBlock (IDT) containing HA fused to FRB*
797 was subcloned into the AgeI and KpnI sites of MYOF-HA (Addgene plasmid, #22443) to generate
798 MYOF Δ TM-HA-FRB* (referred to as MYOF-FRB*). MYOF Δ C2 was generated via PCR
799 amplification from the MYOF-FRB* parent vector. The T192-FLAG-FKBP was a gift from Roberto
800 Zoncu at UC Berkeley.

801

802 **shRNAs and siRNAs**

803 shRNA vectors (pLKO.1 puro) were obtained from the Sigma MISSION TRC shRNA library. The
804 sequences and RNAi Consortium clone IDs for the shRNAs used are as follows: shMYOF#1
805 (human): 5'- GAAAGAGCTGTGCATTATAAA-3' (TRCN0000320397); shMYOF#2 (human): 5'-
806 GAAAGAGCTGTGCATTATAAA-3' (TRCN0000001522); shATG3#1 (human): 5'-
807 GATGTGACCATTGACCATATT-3' (TRCN0000148120); shATG3#2 (human): 5'-
808 GCTGTCATTCCAACAATAGAA-3' (TRCN0000147381); shATG7#1 (human): 5'-
809 CCCAGCTATTGGAACACTGTA-3' (TRCN0000007587); shATG7#2 (human): 5'-
810 GCCTGCTGAGGAGCTCTCCAT-3' (TRCN0000007584); shGFP: 5'-
811 TGCCCGACAACCACTACCTGA-3' (TRCN0000072186). Pre-designed silencer select siRNAs
812 against MYOF were ordered from Thermo Fischer (Cat# 4392420). shGFP and shScr (Addgene,
813 plasmid #17920) were used as controls.

814

815 **Lentiviral-mediated knockdown**

816 For the transfection of lentiviral vectors (pSLIK-hygro, pINDUCER20, and pLKO.1-puro), lentivirus
817 was produced by co-transfection of HEK293T cells with a lentiviral vector and the packaging
818 plasmids psPAX2 (Addgene, plasmid #12260) and pMD2.G (Addgene, plasmid #12259) at a
819 0.5:0.25:0.25 ratio. Transfection was performed using X-tremeGENE transfection (6365787001;
820 Sigma Aldrich) reagent according to the manufacturer's instructions. The viral supernatant was
821 collected 48h after transfection and filtered through a 0.45 μ m filter. Cells were infected with virus-
822 containing media using Polybrene reagent (TR-1003-G; EMD Millipore) according to the
823 manufacturer's instructions and selected for 48 hr in 2 μ g/mL of puromycin.

824

825 **Immunoblotting**

826 Cells were lysed in ice-cold lysis buffer (150 mM NaCl, 20 mM Tris [pH 7.5], 1 mM EDTA, 1 mM
827 EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β -glycerophosphate, 1 mM
828 sodium vanadate, and one tablet of Pierce Protease Inhibitor Tablets, EDTA Free [Fisher
829 Scientific-A32965] per 10 mL). Protein content was measured using Pierce BCA Protein Assay

830 Kit (Life Technologies-23227), and 20-30 µg protein was resolved on 8, 10 or 12% protein gels
831 using SDS-PAGE and transferred onto PVDF membranes (EMD Millipore-IPVH00010).
832 Membranes were blocked in 5% bovine serum albumin (BSA, Sigma Aldrich-A4503) made up in
833 Tris-buffered saline with 0.2% Tween 20 (TBS-T) prior to incubation with primary antibody
834 overnight at 4°C in 5% bovine serum albumin. Membranes were washed in TBS-T and developed
835 after 1h incubation in species-specific horseradish peroxidase-conjugated secondary antibody,
836 visualized using supersignal west pico chemiluminescent substrate (Fisher Scientific-34080), and
837 imaged using the ChemiDoc XRS + System (Biorad).

838

839 **Immunoprecipitation**

840 For lysosome immunoprecipitation experiments, human PDA, HPDE or HEK293T cell lines stably
841 expressing T192-mRFP-3xHA were lysed and intact lysosomes from 1–2 mg of total protein was
842 immunoprecipitated using anti-HA-conjugated Dynabeads (Thermo Sci. 88837) as previously
843 described^{1,2}. Proteinase K (Sigma P.2308) digestion was performed when lysosomes were bound
844 to anti-HA-beads. Increasing concentrations of Proteinase K (0.1, 0.5, 1, 2.5ug/ml) in Proteinase
845 K buffer (33.3mM Hepes, 1mM CaCl₂, pH:7.4) was added to lysosomes bound to anti-HA beads
846 for 15min on ice. Digestion was terminated with 2mM phenylmethylsulfonyl fluoride (final
847 concentration). Lysosomal proteins were separated by SDS-PAGE and proteins were detected
848 by western blotting.

849

850 **Surface Biotinylation assay**

851 The cell surface of KP4 cells and MYOF-HA expressing HEK293T cells was biotinylated on ice
852 using 0.5 mg/ml of EZ-Link™ Sulfo-NHS-SS-Biotin (Thermo Scientific: 21331) for 30min. Cells
853 were washed twice with 20mM Glycine in HBSS on ice to remove excess biotin. Subsequently,
854 cells were lysed in Biotinylation Lysis Buffer (1% Triton X-100, 130mM NaCl, 2.5mM MgCl₂, 2mM
855 EGTA, 25mM HEPES, pH 7.4, supplemented with protease inhibitor prior to use) on ice for 30min.
856 Lysates were clarified by centrifugation at 13,300 rpm for 10min at 4°C and supernatants were
857 transferred to a new tube. Lysates were quantified by Pierce BCA Protein Assay Kit and equal
858 amounts (~1mg) of protein were incubated with 100µl of triple-washed Dynabeads™ MyOne™
859 Streptavidin C1 beads (Invitrogen: 65002) for 2-3h with constant agitation. Beads and captured
860 materials were washed twice in Wash Buffer 1 (2% SDS in dH₂O), once in Wash Buffer 2 (0.1%
861 deoxycholate, 1% Triton X-100, 500mM NaCl, 1mM EDTA, and 50mM HEPES, pH 7.5), once in
862 Wash Buffer 3 (250mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1mM EDTA, and 10mM Tris, pH

863 8.1), and twice in Wash Buffer 4 (50mM Tris, pH 7.4, and 50mM NaCl). Washes were performed
864 at RT for 5min with gentle agitation. Samples were eluted by boiling in Laemlli buffer.

865

866 **FRB-FKBP heterodimerization assay.**

867 U2OS cells stably expressing T192-Flag-FKBP were grown on coverslips and transiently
868 transfected with either MYOF-FRB* or MYOF Δ C2-FRB* using X-tremegene 9 DNA Transfection
869 Reagent (Roche). After 24h, dimerization was induced by adding 100nM of AP21967 (Takara:
870 635056) for 1h to cells. Coverslips were then washed twice prior to treated with 1mM LLOME for
871 the indicated timepoints. Cells were subsequently fixed for immunofluorescent staining.

872

873 **Immunofluorescence**

874 Human cells were cultured for two days on coverslips coated with fibronectin. After two PBS
875 washes, cells were fixed with paraformaldehyde for 15min at room temperature or with ice-cold
876 methanol for 5min at -20^oC. PFA fixed cells were permeabilized with 0.1% Saponin or 0.3% Triton
877 X-100 for 5min. Samples were then blocked with 5% normal goat serum for 15min at room
878 temperature prior to incubation with primary antibodies overnight at 4^oC (Supplementary Table
879 1). After washing three times with PBS, cells were incubated in secondary antibody (diluted 1:400
880 in PBS) at room temperature for 30min. Slides were mounted on glass slides using DAPI
881 Fluoromount-G (0100-20, SouthernBiotech) and imaged on a Zeiss Laser Scanning Microscope
882 (LSM) 710 using a 63x objective. Image processing and quantification were performed using
883 ImageJ. For DQ-BSA experiments, cells were incubated with 200 μ g DQ-BSA for 3h and
884 subsequently chased for 3h in DQ-BSA free media. Where indicated, treatment with BafA1 was
885 for 1h at 100nM. The number of DQ-BSA spots co-localizing with LAMP2 positive lysosomes was
886 quantified. For experiments requiring exposure to LLOMe, silica nanoparticles, hypertonic
887 sucrose or LysoTracker, coverslips were bathed in medium containing the appropriate reagent as
888 indicated, prior to fixing and staining. Measurement of colocalization was conducted using
889 thresholded images using the image calculator function in Image J. Overlapping pixels in the red
890 and green channels were measured and percentage overlap calculated from a minimal of 10
891 fields per condition. For measuring total cell fluorescence, analysis was performed on a per cell
892 basis using Image J. Mean fluorescence intensities for each cell was determined by subtracting
893 the mean fluorescence of the background in each image.

894

895 **Generation of Myoferlin knockout cell lines using CRISPR/Cas9**

896 Myoferlin knockouts in KP4, Patu8902 and FC1245 cells were generated using the RNP-
897 electroporation method as previously described (Liang et al., 2015). One million cells were
898 electroporated using the Amaxa 4D Nucleofector kit (V4XC-9064, Lonza). Guide RNA and Cas9
899 complexes were pre-formed using 160µM crRNA annealed to 160µM tracrRNA (Dharmacon) and
900 incubated with 40µM Cas9 protein (purchased from University of California, Berkeley). Cutting
901 efficiency was assessed 48h post-electroporation using PCR and sanger sequencing. Myoferlin
902 knockout was confirmed using quantitative RT-PCR and immunoblotting after clonal expansion
903 of single cells.

904

905 Guide RNA Sequences (5'-3'):

906 Mouse Myoferlin exon 3 - TGA CTT GAG GGG GAT ACC AC

907 Mouse Myoferlin exon 4 - CTC CCT GAA GGA CCT GAT TG

908 Human MYOFERLIN exon 1 – TTT CGT TTT AGG GAT ATT GC

909 Human MYOFERLIN exon 3 – ATT TTG GAG TTT GAC TTG AG

910

911 PCR Primer Sequences (5'-3'):

912 Ms Myof Ex3 Fwd – tgagtcagaggttggtagacc

913 Ms Myof Ex3 Rev – cagactcgtgacggctgagtat

914 Ms Myof Ex4 Fwd – agccaaagagaggagcatgtgt

915 Ms Myof Ex4 Rev – tatctcaacctcccaactgccg

916 Hu MYOF Ex1 Fwd – GGGAGTTCGGTATCAGTTTACA

917 Hu MYOF Ex1 Rev – CTGGAGAGACTTGGCTTCATC

918 Hu MYOF Ex 3 Fwd – TCAGCTGCCTTCAGGTTTAG

919 Hu MYOF Ex3 Rev – CCACATCTGCTATTGGCTTAGA

920

921 **Histology and immunostaining**

922 Tissue samples were fixed overnight in 10% formalin, and then embedded in paraffin and
923 sectioned (5mm thickness) by the UCSF mouse histopathology core. Haematoxylin and eosin
924 staining was performed using standard methods. Slides were baked at 60°C for a 1h,
925 deparaffinized in xylenes (three treatments, 5 min each), rehydrated sequentially in ethanol (5min
926 in 100%, 5min in 90%, 5min in 70%, 5min in 50%, and 5min in 30%), and washed for 5min in
927 water twice. For antigen unmasking, specimens were cooked in a 10mM sodium citrate buffer (pH
928 6.0) for 10min at 95°C using conventional pressure cooker, rinsed three times with PBS,
929 incubated for 1h with 3% H₂O₂ at room temperature to block endogenous peroxidase activity,

930 washed three times with PBS, and blocked with 2.5% goat serum in PBS for 1h. Primary
931 antibodies were diluted in blocking solution and incubated with the tissue sections at 4°C
932 overnight. Specimens were then washed three times for 5min each in PBS and incubated with
933 secondary anti-mouse/rabbit IgG (Vector Laboratories, MP-7500) or fluorescent-conjugated
934 secondary antibodies (1:500, Supplementary Table 1) at RT for 1h. Following three washes in
935 PBS, slides were stained for peroxidase for 3min with the DAB (di-aminebenzidine) substrate kit
936 (SK-4100, Vector Laboratories), washed with water and counterstained with haematoxylin or
937 mounted on glass slides using DAPI Fluoromount-G. Bright light images were obtained with a
938 with a KEYENCE BZ-X710 microscope. Fluorescent images were obtained with Zeiss Laser
939 Scanning Microscope (LSM) 710.

940

941 **Human Samples**

942 The pancreatic cancer tissue microarray has been previously described³. Clinicopathologic
943 variables used for analysis of the TMA were based on the 7th edition of the AJCC/UICC TNM
944 staging system for pancreatic cancer. Immunohistochemical staining for MYOF was conducted
945 using anti-MYOF ab (Sigma; Cat. No HPA014245). Multiple (2-3) 1.0 mm cores for each tumour
946 in the TMA were independently scored for staining positivity by two pathologists (DWD and KWW)
947 using modified histoscores (range 0-9), representing the product of staining intensity (0-3, 0-
948 absent; 1-weak; 2-moderate; 3-strong) and percentage of tumour cell staining (0-3, 0, none; 1, 1-
949 33%; 2, 34-66%; 3, 67-100%). For any core where histoscore differed by more than 2 between
950 the two observers, a revised score was assigned based on consensus evaluation. The average
951 histoscore for both observers was used for subsequent analysis. For dichotomization, each
952 tumour was assigned to either a low (histoscore 0-5) or high (histoscore >5-9) staining group.
953 Survival estimates were generated using the Kaplan-Meier method and compared using log-rank
954 tests. Multivariate Cox proportional hazards models were used to test statistical independence
955 and significance of multiple predictors with backward selection performed using the Akaike
956 Information Criterion. Overall survival time was measured from the date of surgery to the date of
957 death due to any cause or last clinical visit up to 60 months.

958 PDAC expression data was collected from the following databases: GSE62452, GSE28735,
959 GSE15471, GSE16515, GSE43795. *P* values were calculated by paired or unpaired, two-tailed *t*-
960 test.

961

962 **Animal Experiments**

963 All experiments were carried out in a clean conventional facility. For subcutaneous xenografts, 2
964 million KP4 Cas9 control/MYOF KO or FC1245 Cas9 control/myof KO cells were injected into the
965 flank of nude mice and C57Bl/6 mice respectively (5-6 mice per group). Tumour length and width
966 were measured thrice a week and the volume was calculated according to the formula (length x
967 width²)/2. Mice were euthanized when tumour volume reached 800-1000mm³ and tumours were
968 harvested and submitted for histological examination. Mouse strains were obtained from Jackson
969 Laboratories and kindly provided by colleagues: Ptf1a-Cre (Jax stock no. 019378) mice from C.
970 Wright, LSL-Kras^{G12D} (Jax stock no. 008179) mice from D. Tuveson and T. Jacks and Tp53^{Lox/Lox}
971 (Jax stock no. 008462) mice from A. Berns.

972

973 **Transmission electron microscopy**

974 KP4 cells (control and Myoferlin knockdown cells) grown on tissue culture plates were fixed
975 in 2.5% glutaraldehyde 0.1M sodium cacodylate buffer, pH 7.4 (EMS, Hatfield, PA, USA) for
976 30min at room temperature and then gently scraped using a rubber policeman. Cell pellets were
977 stabilized in 1% low melting point agarose, then cut into 1mm cubes. Samples were rinsed (3x;
978 10min, RT) in 0.1M sodium cacodylate buffer, pH 7.2, and immersed in 1% osmium tetroxide with
979 1.6% potassium ferricyanide in 0.1M sodium cacodylate buffer for 1 hour. Samples were rinsed
980 (3x; 10min, RT) in buffer and then in distilled water (3x; 10min, RT). Sample were immersed in
981 0.5% aqueous uranyl acetate *en bloc* stain for 1h, protected from light and then rinsed in water
982 (3x; 10min, RT). Samples were then subjected to an ascending acetone gradient (10min; 35%,
983 50%, 70%, 80%, 90%) followed by pure acetone (2x; 10min, RT). Samples were progressively
984 infiltrated while rocking with Epon resin (EMS, Hatfield, PA, USA) and polymerized at 60 °C for
985 24-48h. Thin sections (70nm) were cut using a Reichert Ultracut E (Leica, Wetzlar, Germany).
986 Sections were then collected onto formvar-coated 200 mesh copper grids. The grids were post-
987 stained with 2% uranyl acetate followed by Reynold's lead citrate, for 5min each. The sections
988 were imaged using a Tecnai 12 120kV TEM (FEI, Hillsboro, OR, USA) and data recorded using
989 an UltraScan 1000 with Digital Micrograph 3 software (Gatan Inc., Pleasanton, CA, USA).

990

991 **Pathway analysis and statistical analysis**

992 A list of ≥ 2 fold significantly enriched (p -value ≤ 0.05 ; Log₂ fold change ≥ 1) proteins present in
993 PDA lysosome elutes was analyzed for significantly overrepresented gene ontology (GO) terms
994 (Biological Processes) and biological pathways (KEGG) using g:Profiler g:GO St tool⁴ and The
995 Database for Annotation, Visualization and Integrated Discovery (DAVID).

996 Experimental data were analyzed using GraphPad Prism and excel built-in tests and are
997 indicated in the figure legends. For all graphs, error bars indicate mean \pm standard deviation
998 unless otherwise indicated. Numbers of samples analyzed per experiment are reported in the
999 respective figure legends.

1000

1001

1002 **References for methods**

- 1003 1 Zoncu, R. *et al.* mTORC1 senses lysosomal amino acids through an inside-out mechanism
1004 that requires the vacuolar H(+)-ATPase. *Science* **334**, 678-683,
1005 doi:10.1126/science.1207056 (2011).
- 1006 2 Abu-Remaileh, M. *et al.* Lysosomal metabolomics reveals V-ATPase- and mTOR-
1007 dependent regulation of amino acid efflux from lysosomes. *Science* **358**, 807-813,
1008 doi:10.1126/science.aan6298 (2017).
- 1009 3 Manuyakorn, A. *et al.* Cellular histone modification patterns predict prognosis and
1010 treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. *J*
1011 *Clin Oncol* **28**, 1358-1365, doi:10.1200/JCO.2009.24.5639 (2010)
- 1012 4 Raudvere, U. *et al.* g:Profiler: a web server for functional enrichment analysis and
1013 conversions of gene lists. *Nucleic Acids Res* **47**, W191-W198, doi:10.1093/nar/gkz369
1014 (2019).

1015 **Supplementary Tables**

1016

1017 **Table 1:** ≥ 2 fold significantly enriched proteins identified in PDA lysosome elutes.

1018 **Table 2:** Cohort of ≥ 2 fold significantly enriched PDA lysosomal proteins associated with vesicle
1019 trafficking and endocytosis.

1020 **Table 3:** Clinicopathological characteristics and group membership in UCLA TMA.

1021 **Table 4:** Cox proportional hazard models for prognostic factors.

Supplementary Table 1: >2 fold significantly enriched proteins identified in PDA lysosome elutes

Accession Number	avg HEK293T	avg PaTu8988T	fold (PaTu8988T/HEK293T)	ttest	log2 fold change	(-log10 ttest)
NP_001123927	1	89.66667	89.66667	7.1E-05	6.486	4.146
NP_002517	1	68.66667	68.66667	6.5E-06	6.102	5.188
NP_002195	1	52.33333	52.33333	1E-05	5.71	4.993
NP_079105	1	50.66667	50.66667	1.2E-05	5.663	4.936
XP_005264575	0.66667	23.66667	35.5	0.00014	5.15	3.868
XP_005264575	0.66667	23.66667	35.5	0.00014	5.15	3.868
NP_002107	1	34.66667	34.66667	0.00025	5.115	3.606
NP_001290453	1	33.66667	33.66667	8.7E-05	5.073	4.061
NP_001093640	1	32	32	1.1E-05	5	4.941
NP_001193773	1	31.66667	31.66667	0.00096	4.985	3.016
XP_016856023	1	31.33333	31.33333	3.1E-05	4.97	4.507
XP_011543028	1	31	31	0.00013	4.954	3.871
NP_038479	3.66667	108	29.45455	3E-07	4.88	6.52
NP_038479	3.66667	108	29.45455	3E-07	4.88	6.52
NP_001073286	1	27.66667	27.66667	5.2E-05	4.79	4.285
NP_000201	1	27	27	2.3E-05	4.755	4.638
XP_006711978	1	26.66667	26.66667	0.00039	4.737	3.411
XP_016874073	1	26.33333	26.33333	4.5E-05	4.719	4.345
XP_016874073	1	26.33333	26.33333	4.5E-05	4.719	4.345
NP_001073286	1	26.33333	26.33333	0.00014	4.719	3.865
XP_005266132	1	26	26	0.00041	4.7	3.384
NP_004159	1	25	25	0.0024	4.644	2.62
NP_004159	1	25	25	0.0024	4.644	2.62
XP_011514006	1	24	24	0.00134	4.585	2.871
NP_001007069	1	23.33333	23.33333	4.7E-06	4.544	5.325
NP_000253	1	22.66667	22.66667	1.6E-05	4.503	4.788
NP_009220	1	22.33333	22.33333	3.6E-07	4.481	6.447
NP_001007069	1	22.33333	22.33333	5.7E-06	4.481	5.245
NP_000593	1	21.66667	21.66667	2E-05	4.437	4.706
NP_001229971	1	21.33333	21.33333	0.00236	4.415	2.627
NP_001007070	1	21	21	4.1E-06	4.392	5.383
NP_001035861	1	20.66667	20.66667	0.00037	4.369	3.434
XP_016883302	1	18.33333	18.33333	0.00013	4.196	3.872
XP_011531200	1	17.66667	17.66667	4.6E-05	4.143	4.336
NP_001157789	0.66667	11	16.5	0.00344	4.044	2.463
NP_001257904	0.66667	10.66667	16	0.0019	4	2.722
NP_005403	0.66667	10.33333	15.5	0.00292	3.954	2.535

NP_005403	0.66667	10.33333	15.5	0.00292	3.954	2.535
NP_037364	1	15.33333	15.33333	0.00356	3.939	2.448
NP_005219	4.66667	70.33333	15.07143	0.00012	3.914	3.922
NP_005219	4.66667	70.33333	15.07143	0.00012	3.914	3.922
NP_443164	1	14.66667	14.66667	0.00149	3.874	2.825
NP_057231	0.66667	9.66667	14.5	0.00067	3.858	3.172
NP_001679	0.66667	9.66667	14.5	0.00882	3.858	2.054
NP_065843	1	14.33333	14.33333	0.00038	3.841	3.425
NP_001247419	1	13.66667	13.66667	0.00199	3.773	2.701
NP_000916	1	13.66667	13.66667	0.00199	3.773	2.701
XP_016856023	2.66667	35	13.125	2.4E-05	3.714	4.617
NP_001611	8.66667	112	12.92308	0.00141	3.692	2.851
NP_001611	8.66667	112	12.92308	0.00141	3.692	2.851
NP_003557	2.33333	29.66667	12.71429	0.00057	3.668	3.241
NP_060530	1	12.66667	12.66667	4E-06	3.663	5.4
NP_001020527	1	12.66667	12.66667	0.00063	3.663	3.2
NP_001020527	1	12.66667	12.66667	0.00063	3.663	3.2
NP_004915	5.66667	71	12.52941	3.2E-06	3.647	5.499
XP_011528984	1.33333	16.33333	12.25	0.00279	3.615	2.555
NP_003253	0.66667	8	12	0.00114	3.585	2.942
NP_006283	1	12	12	0.00197	3.585	2.705
NP_001171114	0.66667	8	12	0.01169	3.585	1.932
NP_000518	1.33333	15.66667	11.75	0.00065	3.555	3.184
NP_004915	4.66667	53.33333	11.42857	1.9E-05	3.515	4.725
NP_001690	1	11.33333	11.33333	0.00101	3.503	2.998
NP_000174	1	11.33333	11.33333	0.00272	3.503	2.566
NP_000174	1	11.33333	11.33333	0.00272	3.503	2.566
XP_006718556	1	11	11	0.00056	3.459	3.25
NP_079472	0.66667	7.33333	11	0.00086	3.459	3.063
NP_001017423	1.33333	14.33333	10.75	0.00124	3.426	2.905
NP_001093	3.66667	39	10.63636	2.9E-05	3.411	4.534
NP_891988	4.33333	45.66667	10.53846	3.1E-06	3.398	5.515
XP_006717309	2.66667	28	10.5	1.8E-05	3.392	4.75
NP_003840	1.33333	14	10.5	0.00199	3.392	2.701
NP_570846	1	10.33333	10.33333	0.01001	3.369	2
NP_006491	1	10	10	9.9E-05	3.322	4.005
NP_006491	1	10	10	9.9E-05	3.322	4.005
NP_079199	1.66667	16.33333	9.8	0.00204	3.293	2.691
NP_079199	1.66667	16.33333	9.8	0.00204	3.293	2.691
NP_000010	1.66667	16	9.6	0.00579	3.263	2.237
NP_006102	1	9.33333	9.33333	0.0007	3.222	3.155
NP_000681	1	9.33333	9.33333	0.00227	3.222	2.644
NP_001136336	0.66667	6	9	8.9E-05	3.17	4.05

XP_011512751	1	9	9	0.00228	3.17	2.642
NP_003970	1	9	9	0.00228	3.17	2.642
NP_001289561	1	9	9	0.00635	3.17	2.197
NP_001289561	1	9	9	0.00635	3.17	2.197
NP_001034579	1	9	9	0.01613	3.17	1.792
NP_004484	0.66667	6	9	0.0329	3.17	1.483
NP_001449	4	35.33333	8.833333	0.00036	3.143	3.447
XP_005248242	1	8.666667	8.666667	0.00033	3.115	3.486
NP_000134	1	8.666667	8.666667	0.0031	3.115	2.509
NP_071436	1	8.333333	8.333333	0.00039	3.059	3.411
NP_002626	1	8.333333	8.333333	0.01417	3.059	1.849
NP_000204	1	8.333333	8.333333	0.0168	3.059	1.775
NP_000204	1	8.333333	8.333333	0.0168	3.059	1.775
NP_036475	1	8.333333	8.333333	0.02844	3.059	1.546
NP_000970	1.33333	11	8.25	0.00192	3.044	2.716
XP_016869431	4.33333	35.66667	8.230769	7.7E-05	3.041	4.114
NP_037506	4.66667	38.33333	8.214286	0.00518	3.038	2.286
NP_037506	4.66667	38.33333	8.214286	0.00518	3.038	2.286
NP_002831	2.66667	21.66667	8.125	2.3E-06	3.022	5.645
NP_009055	1	8	8	0.00027	3	3.576
NP_009055	1	8	8	0.00027	3	3.576
NP_955394	2	16	8	0.00374	3	2.427
NP_001309906	1	8	8	0.00374	3	2.427
NP_001309906	1	8	8	0.00374	3	2.427
NP_001186913	1	8	8	0.01016	3	1.993
NP_001688	1	8	8	0.0249	3	1.604
NP_955394	2	15.66667	7.833333	0.00378	2.97	2.423
NP_001001937	7.33333	57	7.772727	0.00071	2.958	3.151
NP_001310245	1	7.666667	7.666667	0.00056	2.939	3.25
NP_001310245	1	7.666667	7.666667	0.00056	2.939	3.25
NP_061329	1	7.666667	7.666667	0.00749	2.939	2.125
NP_001177910	0.66667	5	7.5	0.00797	2.907	2.099
NP_001177910	0.66667	5	7.5	0.00797	2.907	2.099
NP_056991	1	7.333333	7.333333	0.00199	2.874	2.701
XP_016881019	1	7.333333	7.333333	0.00897	2.874	2.047
XP_016881019	1	7.333333	7.333333	0.00897	2.874	2.047
XP_006716370	1	7.333333	7.333333	0.0191	2.874	1.719
NP_000173	2.33333	17	7.285714	0.00446	2.865	2.351
NP_001230209	2.33333	17	7.285714	0.00579	2.865	2.238
NP_001089	1	7	7	0.00048	2.807	3.315
NP_000681	1	7	7	0.00388	2.807	2.411
NP_003356	1	7	7	0.01324	2.807	1.878
NP_004386	1	7	7	0.03032	2.807	1.518

NP_490647	3.66667	24.66667	6.727273	0.01092	2.75	1.962
NP_055635	1	6.666667	6.666667	7E-05	2.737	4.154
NP_003357	1	6.666667	6.666667	0.00105	2.737	2.979
NP_005551	1	6.666667	6.666667	0.00302	2.737	2.521
NP_005994	1	6.666667	6.666667	0.00921	2.737	2.036
NP_005995	1	6.666667	6.666667	0.03251	2.737	1.488
NP_005995	1	6.666667	6.666667	0.03251	2.737	1.488
NP_066925	2.66667	17.66667	6.625	0.0004	2.728	3.398
NP_490647	3.66667	24	6.545455	0.01403	2.71	1.853
NP_002831	3.33333	21.66667	6.5	4.1E-05	2.7	4.385
NP_002380	0.66667	4.333333	6.5	0.00793	2.7	2.101
NP_076997	0.66667	4.333333	6.5	0.02947	2.7	1.531
NP_004433	1	6.333333	6.333333	8.9E-05	2.663	4.05
XP_016873572	1	6.333333	6.333333	0.00132	2.663	2.878
NP_002834	1	6.333333	6.333333	0.00132	2.663	2.878
NP_005594	1	6.333333	6.333333	0.00377	2.663	2.423
NP_001922	1	6.333333	6.333333	0.01135	2.663	1.945
NP_002283	1	6.333333	6.333333	0.01613	2.663	1.792
NP_038470	1.33333	8.333333	6.25	0.00702	2.644	2.154
NP_038470	1.33333	8.333333	6.25	0.00702	2.644	2.154
NP_057494	0.66667	4	6	0.00056	2.585	3.25
XP_006713173	0.66667	4	6	0.00749	2.585	2.125
XP_005273672	1	6	6	0.01235	2.585	1.908
NP_001139433	4.66667	27	5.785714	2.9E-05	2.532	4.533
NP_001291395	1	5.666667	5.666667	0.00015	2.503	3.821
NP_003349	1	5.666667	5.666667	0.00015	2.503	3.821
NP_001157666	1	5.666667	5.666667	0.00219	2.503	2.659
NP_006280	1	5.666667	5.666667	0.00612	2.503	2.213
NP_006280	1	5.666667	5.666667	0.00612	2.503	2.213
NP_001317939	1	5.666667	5.666667	0.04055	2.503	1.392
NP_001317939	1	5.666667	5.666667	0.04055	2.503	1.392
NP_001677	11	62	5.636364	2.2E-05	2.495	4.66
NP_004068	2	11	5.5	0.00529	2.459	2.277
NP_000777	0.66667	3.666667	5.5	0.0158	2.459	1.801
NP_002380	0.66667	3.666667	5.5	0.0158	2.459	1.801
NP_001164187	0.66667	3.666667	5.5	0.0158	2.459	1.801
NP_001164187	0.66667	3.666667	5.5	0.0158	2.459	1.801
XP_016869235	1.66667	9	5.4	0.01955	2.433	1.709
NP_005836	1	5.333333	5.333333	0.0002	2.415	3.695
NP_005836	1	5.333333	5.333333	0.0002	2.415	3.695
NP_001185470	1	5.333333	5.333333	0.0002	2.415	3.695
NP_001309896	1	5.333333	5.333333	0.00289	2.415	2.539
NP_001001973	1	5.333333	5.333333	0.00289	2.415	2.539

NP_002296	1	5.333333	5.333333	0.00289	2.415	2.539
NP_714916	1	5.333333	5.333333	0.00797	2.415	2.099
NP_714916	1	5.333333	5.333333	0.00797	2.415	2.099
NP_004544	1	5.333333	5.333333	0.00797	2.415	2.099
NP_000117	1	5.333333	5.333333	0.00797	2.415	2.099
NP_006467	1	5.333333	5.333333	0.00797	2.415	2.099
NP_055755	1	5.333333	5.333333	0.02265	2.415	1.645
NP_036450	1	5.333333	5.333333	0.04064	2.415	1.391
NP_006787	1	5.333333	5.333333	0.04064	2.415	1.391
NP_006787	1	5.333333	5.333333	0.04064	2.415	1.391
NP_001098707	1.66667	8.666667	5.2	0.00495	2.379	2.305
NP_001098707	1.66667	8.666667	5.2	0.00495	2.379	2.305
NP_036313	1.33333	6.666667	5	0.0085	2.322	2.071
NP_001317170	0.66667	3.333333	5	0.02322	2.322	1.634
NP_001616	0.66667	3.333333	5	0.04742	2.322	1.324
NP_001668	2	10	5	0.00228	2.322	2.642
NP_056167	1	5	5	0.00228	2.322	2.642
NP_001014446	1	5	5	0.00228	2.322	2.642
NP_001166925	1	5	5	0.01613	2.322	1.792
NP_001166925	1	5	5	0.01613	2.322	1.792
NP_009034	1	5	5	0.01613	2.322	1.792
NP_057218	1	5	5	0.01613	2.322	1.792
NP_071358	2.33333	11.33333	4.857143	0.00882	2.28	2.054
NP_001139433	5.66667	27.33333	4.823529	9.5E-05	2.27	4.024
NP_006507	3.66667	17.33333	4.727273	0.00039	2.241	3.404
NP_000137	14.3333	67.66667	4.72093	0.04029	2.239	1.395
NP_000144	4.33333	20.33333	4.692308	0.00304	2.23	2.518
NP_003181	1	4.666667	4.666667	0.00039	2.222	3.411
NP_056437	1	4.666667	4.666667	0.00039	2.222	3.411
NP_002309	1	4.666667	4.666667	0.00039	2.222	3.411
NP_689632	1	4.666667	4.666667	0.00039	2.222	3.411
NP_689632	1	4.666667	4.666667	0.00039	2.222	3.411
NP_006347	1	4.666667	4.666667	0.038	2.222	1.42
NP_006347	1	4.666667	4.666667	0.038	2.222	1.42
NP_004125	14	64.66667	4.619048	0.00061	2.208	3.215
NP_596867	18	82	4.555556	1E-05	2.188	4.996
NP_001291217	0.66667	3	4.5	0.00219	2.17	2.659
NP_057086	0.66667	3	4.5	0.00219	2.17	2.659
NP_003835	0.66667	3	4.5	0.00219	2.17	2.659
NP_001309997	0.66667	3	4.5	0.0249	2.17	1.604
XP_011511426	1.66667	7.333333	4.4	0.01908	2.138	1.719
XP_011511426	1.66667	7.333333	4.4	0.01908	2.138	1.719
NP_000427	1	4.333333	4.333333	0.00056	2.115	3.25

NP_000427	1	4.333333	4.333333	0.00056	2.115	3.25
XP_016871724	1	4.333333	4.333333	0.00056	2.115	3.25
XP_016871716	1	4.333333	4.333333	0.00056	2.115	3.25
NP_004246	1	4.333333	4.333333	0.00056	2.115	3.25
NP_056417	1	4.333333	4.333333	0.00749	2.115	2.125
NP_003650	1	4.333333	4.333333	0.00749	2.115	2.125
NP_006342	1	4.333333	4.333333	0.00749	2.115	2.125
NP_056138	1	4.333333	4.333333	0.01944	2.115	1.711
NP_065724	2.33333	10	4.285714	0.00802	2.1	2.096
NP_002071	8	34	4.25	0.00105	2.087	2.981
NP_002071	8	34	4.25	0.00105	2.087	2.981
NP_003312	8.33333	34.66667	4.16	0.00015	2.057	3.817
NP_003312	8.33333	34.66667	4.16	0.00015	2.057	3.817
NP_001070952	1.66667	6.66667	4	0.00607	2	2.217
NP_001001563	1	4	4	0.00653	2	2.185
NP_001254792	1	4	4	0.00653	2	2.185
XP_006715894	1	4	4	0.00653	2	2.185
XP_006715894	1	4	4	0.00653	2	2.185
NP_001317504	1	4	4	0.00653	2	2.185
NP_002990	1	4	4	0.00653	2	2.185
NP_001271342	1	4	4	0.00653	2	2.185
NP_006741	1	4	4	0.00653	2	2.185
NP_006741	1	4	4	0.00653	2	2.185
NP_002817	1	4	4	0.00653	2	2.185
NP_963906	1	4	4	0.03994	2	1.399
NP_004039	2.33333	9.333333	4	0.0485	2	1.314
NP_001327	22.3333	88.66667	3.970149	0.00215	1.989	2.667
NP_001193769	13.3333	52.66667	3.95	0.00219	1.982	2.66
NP_001080	10.3333	40.66667	3.935484	0.00026	1.977	3.581
XP_011532413	3	11.66667	3.888889	0.0002	1.959	3.695
NP_001193769	13.3333	51.66667	3.875	0.00241	1.954	2.618
NP_001104547	5	19.33333	3.866667	0.00579	1.951	2.237
NP_005262	4	15.33333	3.833333	0.00921	1.939	2.036
NP_001269555	6.66667	24.66667	3.7	0.00045	1.888	3.347
NP_001269555	6.66667	24.66667	3.7	0.00045	1.888	3.347
NP_004578	9.33333	34.33333	3.678571	0.00202	1.879	2.694
NP_004578	9.33333	34.33333	3.678571	0.00202	1.879	2.694
NP_001159434	1	3.666667	3.666667	0.00132	1.874	2.878
XP_011536954	1	3.666667	3.666667	0.00132	1.874	2.878
NP_001139630	1	3.666667	3.666667	0.00132	1.874	2.878
NP_733746	2	7.333333	3.666667	0.00718	1.874	2.144
NP_066972	1	3.666667	3.666667	0.01613	1.874	1.792
NP_036335	1	3.666667	3.666667	0.03902	1.874	1.409

NP_036335	1	3.666667	3.666667	0.03902	1.874	1.409
NP_001273300	1	3.666667	3.666667	0.03902	1.874	1.409
NP_001273300	1	3.666667	3.666667	0.03902	1.874	1.409
NP_002547	8.66667	31.33333	3.615385	0.00081	1.854	3.09
NP_005909	10	35	3.5	0.0009	1.807	3.044
NP_001106818	12	41.66667	3.472222	9.5E-06	1.796	5.023
XP_011541265	4.33333	15	3.461538	0.00306	1.791	2.514
XP_011541265	4.33333	15	3.461538	0.00306	1.791	2.514
NP_008879	3.33333	11.33333	3.4	0.00194	1.766	2.713
NP_001094096	3.66667	12.33333	3.363636	0.00078	1.75	3.109
NP_001015	1	3.333333	3.333333	0.00219	1.737	2.659
NP_002812	1	3.333333	3.333333	0.00219	1.737	2.659
NP_000194	1	3.333333	3.333333	0.00219	1.737	2.659
NP_057055	1	3.333333	3.333333	0.00219	1.737	2.659
NP_001273432	2	6.666667	3.333333	0.01145	1.737	1.941
NP_001273432	2	6.666667	3.333333	0.01145	1.737	1.941
NP_002083	1	3.333333	3.333333	0.0249	1.737	1.604
NP_002793	1	3.333333	3.333333	0.0249	1.737	1.604
NP_002793	1	3.333333	3.333333	0.0249	1.737	1.604
NP_001924	1	3.333333	3.333333	0.0249	1.737	1.604
NP_037460	1	3.333333	3.333333	0.0249	1.737	1.604
NP_037460	1	3.333333	3.333333	0.0249	1.737	1.604
NP_002799	4	13	3.25	0.00146	1.7	2.835
NP_002799	4	13	3.25	0.00146	1.7	2.835
NP_060154	3.33333	10.33333	3.1	0.00934	1.632	2.03
NP_060154	3.33333	10.33333	3.1	0.00934	1.632	2.03
NP_001120699	7	21.66667	3.095238	0.00365	1.63	2.438
NP_056083	12	36.33333	3.027778	0.00374	1.598	2.427
NP_001018121	3.33333	10	3	0.01301	1.585	1.886
NP_001280202	0.66667	2	3	0.01613	1.585	1.792
NP_001280202	0.66667	2	3	0.01613	1.585	1.792
NP_000981	0.66667	2	3	0.01613	1.585	1.792
XP_016872987	0.66667	2	3	0.01613	1.585	1.792
NP_001139541	0.66667	2	3	0.01613	1.585	1.792
NP_055621	0.66667	2	3	0.01613	1.585	1.792
NP_001265124	1	3	3	0.02572	1.585	1.59
NP_001138471	1	3	3	0.02572	1.585	1.59
NP_001265392	1	3	3	0.02572	1.585	1.59
NP_001265392	1	3	3	0.02572	1.585	1.59
NP_149100	1	3	3	0.02572	1.585	1.59
NP_001352	1	3	3	0.02572	1.585	1.59
NP_001121132	1	3	3	0.02572	1.585	1.59
NP_001143	6	17.66667	2.944444	0.00038	1.558	3.421

NP_076424	3	8.666667	2.888889	0.03251	1.531	1.488
NP_003642	5.66667	16.33333	2.882353	0.04742	1.527	1.324
NP_001192183	2.33333	6.666667	2.857143	0.00436	1.515	2.361
NP_009216	2	5.666667	2.833333	0.02539	1.503	1.595
NP_877420	3.33333	9.333333	2.8	0.00559	1.485	2.253
NP_001171903	1.66667	4.666667	2.8	0.03347	1.485	1.475
NP_001143	7.66667	21.33333	2.782609	0.00039	1.476	3.404
NP_054735	13.6667	38	2.780488	5.3E-05	1.475	4.276
NP_054735	13.6667	38	2.780488	5.3E-05	1.475	4.276
NP_001627	6	16.66667	2.777778	0.00054	1.474	3.27
NP_001367	3	8.333333	2.777778	0.00718	1.474	2.144
NP_955472	53.3333	147.3333	2.7625	0.00247	1.466	2.607
NP_001189414	12	33	2.75	0.00301	1.459	2.522
NP_113651	1.33333	3.666667	2.75	0.03517	1.459	1.454
NP_003944	1.33333	3.666667	2.75	0.03517	1.459	1.454
NP_001825	2	5.333333	2.666667	0.00056	1.415	3.25
NP_689601	1	2.666667	2.666667	0.00749	1.415	2.125
NP_689450	1	2.666667	2.666667	0.00749	1.415	2.125
NP_001316143	1	2.666667	2.666667	0.00749	1.415	2.125
NP_057292	1	2.666667	2.666667	0.00749	1.415	2.125
NP_001000	1	2.666667	2.666667	0.00749	1.415	2.125
NP_079172	1	2.666667	2.666667	0.00749	1.415	2.125
NP_001245366	1	2.666667	2.666667	0.00749	1.415	2.125
NP_006779	3.66667	9.666667	2.636364	0.00129	1.399	2.888
NP_003036	6.33333	16.66667	2.631579	2.6E-05	1.396	4.591
NP_000099	4.33333	11.33333	2.615385	0.00012	1.387	3.922
NP_789782	5	13	2.6	0.04179	1.379	1.379
NP_001351	1.66667	4.333333	2.6	0.04742	1.379	1.324
NP_710154	3	7.666667	2.555556	0.0249	1.354	1.604
NP_002818	3	7.666667	2.555556	0.04881	1.354	1.311
NP_631918	9	22.66667	2.518519	0.00424	1.333	2.373
NP_001138303	5.33333	13.33333	2.5	0.00582	1.322	2.235
NP_003477	3.33333	8.333333	2.5	0.022	1.322	1.658
NP_006422	13.6667	34	2.487805	0.02036	1.315	1.691
NP_002625	7.66667	19	2.478261	0.00105	1.309	2.979
NP_002625	7.66667	19	2.478261	0.00105	1.309	2.979
XP_016873370	7	17.33333	2.47619	0.00207	1.308	2.685
XP_016873370	7	17.33333	2.47619	0.00207	1.308	2.685
NP_848927	3.66667	9	2.454545	0.00377	1.295	2.423
NP_003833	2.33333	5.666667	2.428571	0.02411	1.28	1.618
NP_001315615	25	60.66667	2.426667	0.00238	1.279	2.624
XP_011534504	5	12	2.4	0.00374	1.263	2.427
NP_002148	18.6667	44.66667	2.392857	0.00296	1.259	2.528

NP_000375	5.33333	12.66667	2.375	0.00268	1.248	2.572
NP_002435	5.33333	12.66667	2.375	0.04911	1.248	1.309
NP_001656	3.66667	8.666667	2.363636	0.00045	1.241	3.349
NP_006030	3.66667	8.666667	2.363636	0.00257	1.241	2.59
XP_005259654	1	2.333333	2.333333	0.01613	1.222	1.792
XP_005259654	1	2.333333	2.333333	0.01613	1.222	1.792
NP_001018080	1	2.333333	2.333333	0.01613	1.222	1.792
NP_001128567	1	2.333333	2.333333	0.01613	1.222	1.792
NP_001311211	1	2.333333	2.333333	0.01613	1.222	1.792
NP_001280134	1	2.333333	2.333333	0.01613	1.222	1.792
NP_000683	1	2.333333	2.333333	0.01613	1.222	1.792
XP_016876295	1	2.333333	2.333333	0.01613	1.222	1.792
XP_016876295	1	2.333333	2.333333	0.01613	1.222	1.792
NP_689518	1	2.333333	2.333333	0.01613	1.222	1.792
NP_919415	19.6667	45.66667	2.322034	0.00132	1.215	2.879
NP_002148	20.3333	46.66667	2.295082	0.00212	1.199	2.674
NP_004550	8.66667	19.33333	2.230769	0.00103	1.158	2.989
NP_001020331	3.33333	7.333333	2.2	0.00582	1.138	2.235
NP_001020331	3.33333	7.333333	2.2	0.00582	1.138	2.235
XP_011529429	7.66667	16.66667	2.173913	0.0226	1.12	1.646
NP_001072989	15.6667	33.66667	2.148936	0.04361	1.104	1.36
NP_004550	9.33333	20	2.142857	0.00306	1.1	2.514
NP_001002814	5.66667	12	2.117647	0.00386	1.082	2.413
XP_005258336	46.6667	98.33333	2.107143	0.00015	1.075	3.825
NP_002061	22.6667	47.66667	2.102941	0.0005	1.072	3.3
NP_001336864	4.66667	9.666667	2.071429	0.02846	1.051	1.546
NP_002363	5.33333	11	2.0625	0.02227	1.044	1.652
NP_002363	5.33333	11	2.0625	0.02227	1.044	1.652
NP_938148	34	70	2.058824	0.00051	1.042	3.292
NP_000503	10.3333	21	2.032258	0.03594	1.023	1.444
NP_000503	10.3333	21	2.032258	0.03594	1.023	1.444
NP_002385	23	46.33333	2.014493	4E-06	1.01	5.4
NP_002385	23	46.33333	2.014493	4E-06	1.01	5.4
NP_061849	3.33333	6.666667	2	0.00211	1	2.676
NP_055422	2.33333	4.666667	2	0.00776	1	2.11
XP_016860258	3.66667	7.333333	2	0.00793	1	2.101
NP_004595	2.66667	5.333333	2	0.02322	1	1.634
NP_004595	2.66667	5.333333	2	0.02322	1	1.634

Supplementary Table 2: Cohort of >2 fold significantly enriched PDA lysosomal proteins associated with vesicle trafficking and endocytosis

Accession Number	Protein Name	Present within the GO Biological Process category "endocytosis" GO: 0006897
NP_005836	ATP binding cassette subfamily C member 4(ABCC4)	
NP_001690	AXL receptor tyrosine kinase(AXL)	X
NP_056437	CCZ1 homolog, vacuolar protein trafficking and biogenesis associated(CCZ1)	
XP_011512751	CD2 associated protein(CD2AP)	X
NP_001120699	CD59 molecule(CD59)	
NP_056083	DnaJ heat shock protein family (Hsp40) member C13(DNAJC13)	
NP_009216	GABA type A receptor associated protein like 2(GABARAPL2)	
NP_055755	MON1 homolog B, secretory trafficking associated(MON1B)	
NP_000262 / XP_001002814	NPC intracellular cholesterol transporter 1(NPC1)	X
NP_001002814	RAB11 family interacting protein 1(RAB11FIP1)	
NP_065724	RAB22A, member RAS oncogene family(RAB22A)	X
NP_003181	TAP binding protein(TAPBP)	
NP_919415	VAMP associated protein A(VAPA)	
NP_057292	VPS28, ESCRT-I subunit(VPS28)	X
NP_001093	actinin alpha 1(ACTN1)	
NP_004915	actinin alpha 4(ACTN4)	X
NP_001315615	amyloid beta precursor like protein 2(APLP2)	
NP_001020527	anoctamin 6(ANO6)	X
NP_000375	apolipoprotein B(APOB)	X
XP_006718556	atlastin GTPase 3(ATL3)	
NP_004039	beta-2-microglobulin(B2M)	X
NP_001327	cathepsin Z(CTSZ)	
NP_789782	charged multivesicular body protein 4B(CHMP4B)	
NP_057494	charged multivesicular body protein 5(CHMP5)	
NP_001825	clathrin light chain B(CLTB)	X
NP_001098707	coronin 1C(CORO1C)	X
NP_001265392	dynamin 1 like(DNM1L)	X
NP_001367	dynein cytoplasmic 1 heavy chain 1(DYNC1H1)	

NP_003557	early endosome antigen 1(EEA1)	X
NP_005219	epidermal growth factor receptor(EGFR)	X
NP_001104547	ezrin(EZR)	X
XP_016871724	family with sequence similarity 21 member A(FAM21A)	
XP_011529429	filamin A(FLNA)	
XP_006713173	golgin A4(GOLGA4)	
NP_001273432	heat shock protein family H (Hsp110) member 1(HSPH1)	X
NP_001138471	integrin subunit alpha V(ITGAV)	X
NP_596867	integrin subunit beta 1(ITGB1)	X
NP_001317939	intersectin 1(ITSN1)	X
NP_000518	low density lipoprotein receptor(LDLR)	X
NP_002309	lysyl oxidase like 2(LOXL2)	X
NP_006030	mannose receptor C type 2(MRC2)	X
NP_002435	moesin(MSN)	
NP_002547	oxysterol binding protein like 1A(OSBPL1A)	
NP_001157666	perilipin 3(PLIN3)	
NP_037364	programmed cell death 6 interacting protein(PDCD6IP)	
NP_001171903	protein kinase C and casein kinase substrate in neurons 3(PACSIN3)	X
NP_002818	protein tyrosine phosphatase, non-receptor type 1(PTPN1)	
NP_002817	quiescin sulfhydryl oxidase 1(QSOX1)	
NP_006779	ralA binding protein 1(RALBP1)	X
NP_000593	serpin family E member 1(SERPINE1)	X
NP_001311211	signal transducing adaptor molecule(STAM)	
XP_011541265	sortilin related receptor 1(SORL1)	X
NP_689450	sorting nexin 11(SNX11)	X
XP_006717309	spectrin alpha, non-erythrocytic 1(SPTAN1)	
XP_005264575	spectrin beta, non-erythrocytic 1(SPTBN1)	
NP_002990	syndecan 4(SDC4)	
NP_001007069	syndecan binding protein(SDCBP)	X
NP_004595	syntaxin 4(STX4)	
NP_006280	talin 1(TLN1)	
NP_001310245	transglutaminase 2(TGM2)	X
NP_006283	tumor susceptibility 101(TSG101)	X
NP_060154	vacuolar protein sorting 13 homolog C(VPS13C)	
NP_001273300	vesicle trafficking 1(VTA1)	

Supplementary Table 3: Clinicopathological characteristics and group membership in ULCA TMA (encompassing resected stage I/II pancreatic cancer)

Clinicopathologic Category	MYOF IHC staining		
	Low	High	p-value ^a
Total patients (n)	105	31	N/A
Median Age (yrs)	63.7	65.4	N/A
Gender			
Male	63 (60%)	10 (32%)	0.006
Female	42 (40%)	21 (68%)	
Histologic grade^c			
Low	61 (58%)	14 (45%)	0.2
High	44 (42%)	17 (55%)	
pT (categorized)			
T1+T2	17 (16%)	8 (26%)	0.29
T2	45 (43%)	9 (29%)	
T3	43 (41%)	14 (45%)	
pN (categorized)			
N0	54 (51%)	12 (39%)	0.21
N1	51 (49%)	19 (61%)	
AJCC Stage			
I	33 (31%)	6 (19%)	0.19
II	72 (69%)	25 (81%)	
Surgical Margins			
R0	92 (88%)	28 (90%)	0.68
R1	13 (12%)	3 (10%)	
Tumor size (categorized)			
< 3 cm	64 (61%)	16 (52%)	0.35
≥ 3 cm	41 (39%)	15 (48%)	

^a p-values for Chi square test; Low staining =bottom three quartiles (histoscore 0-5); high staining=top quartile (histoscore >5-9). Variables based on the 7th edition of the AJCC/UICC TNM staging system for pancreatic cancer.

Supplementary Table 4 : Cox proportional hazard models for prognostic factors

A) Univariate Cox Analysis of overall survival in pancreatic cancer TMA

IHC Group	Overall Survival	
	Adjusted HR* (95% CI)	p-value†
High MYOF expression	2.03 (1.29 – 3.19)	0.002

B) Multivariate proportional hazards analysis of overall survival in pancreatic cancer TMA

Variable	Overall Survival	
	Adjusted HR* (95% CI)	p-value†
High MYOF expression	1.98 (1.25 – 3.12)	0.004
High grade histology	2.04 (1.34 – 3.09)	0.001
Lymph node involvement	2.03 (1.34 – 3.08)	0.001
Lower pT status	0.70 (0.53 – 0.92)	0.002

*HR (Hazard Ratio): HR of 1 indicates no difference between the two groups of patients for the listed variable, while a HR > 1 indicates an increased risk of death/failure for the group listed. †p-value from Chi-square test using the Cox proportional hazards model. The following covariates were initially evaluated in a Cox proportional hazards model with backward selection: 1. Lymph node involvement (pN0 vs. pN1), 2. Histologic grade (Low vs. High), 3. T-stage (pT1-pT3), 4. Tumor size (<3 vs. ≥3 cm), 5. Age (<60 vs. ≥60 yrs), 6. Gender, 7. Surgical margin status (negative vs. positive), 8. MYOF expression (low vs. high).